<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Radiol Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Radiol Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">1836</journal-id><journal-id journal-id-type="pmc-domain">radonc</journal-id><journal-id journal-id-type="publisher-id">RADO</journal-id><journal-title-group><journal-title>Radiology and Oncology</journal-title></journal-title-group><issn pub-type="ppub">1318-2099</issn><issn pub-type="epub">1581-3207</issn><publisher><publisher-name>De Gruyter</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC3573828</article-id><article-id pub-id-type="pmcid-ver">PMC3573828.1</article-id><article-id pub-id-type="pmcaid">3573828</article-id><article-id pub-id-type="pmcaiid">3573828</article-id><article-id pub-id-type="pmid">23450046</article-id><article-id pub-id-type="doi">10.2478/raon-2013-0008</article-id><article-id pub-id-type="publisher-id">rado-47-01-01</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Oral treatment with etoposide in small cell lung cancer &#8211; dilemmas and solutions</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Rezonja</surname><given-names initials="R">Renata</given-names></name><xref ref-type="aff" rid="af2-rado-47-01-01"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Knez</surname><given-names initials="L">Lea</given-names></name><xref ref-type="aff" rid="af3-rado-47-01-01"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cufer</surname><given-names initials="T">Tanja</given-names></name><xref ref-type="aff" rid="af3-rado-47-01-01"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mrhar</surname><given-names initials="A">Ales</given-names></name><xref ref-type="aff" rid="af1-rado-47-01-01"><sup>1</sup></xref><xref ref-type="corresp" rid="c1-rado-47-01-01"/></contrib></contrib-group><aff id="af1-rado-47-01-01"><label>1</label> Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia</aff><aff id="af2-rado-47-01-01"><label>2</label> Krka, d.d., Novo mesto, Slovenia</aff><aff id="af3-rado-47-01-01"><label>3</label> University Clinic Golnik, Golnik, Slovenia</aff><author-notes><corresp id="c1-rado-47-01-01">Correspondence to: Prof Ale&#353; Mrhar, PhD, Faculty of Pharmacy, University of Ljubljana, A&#353;ker&#269;eva 7, SI-1000 Ljubljana, Slovenia. Phone: +386 1 4769 541; Fax: +386 14258 031; E-mail: <email>ales.mrhar@ffa.uni-lj.si</email></corresp></author-notes><pub-date pub-type="collection"><month>3</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>01</day><month>2</month><year>2013</year></pub-date><volume>47</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">219696</issue-id><fpage>1</fpage><lpage>13</lpage><history><date date-type="received"><day>14</day><month>9</month><year>2012</year></date><date date-type="accepted"><day>08</day><month>11</month><year>2012</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>03</month><year>2013</year></date></event><event event-type="pmc-live"><date><day>01</day><month>03</month><year>2013</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2013-03-24 11:17:43.020"><day>24</day><month>03</month><year>2013</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; by Association of Radiology &amp; Oncology</copyright-statement><copyright-year>2013</copyright-year><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="rado-47-01-01.pdf"/><abstract><sec><title>Background</title><p>Etoposide is a chemotherapeutic agent, widely used for the treatment of various malignancies, including small cell lung cancer (SCLC), an aggressive disease with poor prognosis. Oral etoposide administration exhibits advantages for the quality of life of the patient as well as economic benefits. However, widespread use of oral etoposide is limited by incomplete and variable bioavailability. Variability in bioavailability was observed both within and between patients. This suggests that some patients may experience suboptimal tumor cytotoxicity, whereas other patients may be at risk for excess toxicity.</p></sec><sec><title>Conclusions</title><p>The article highlights dilemmas as well as solutions regarding oral treatment with etoposide by presenting and analyzing relevant literature data. Numerous studies have shown that bioavailability of etoposide is influenced by genetic, physiological and environmental factors. Several strategies were explored to improve bioavailability and to reduce pharmacokinetic variability of oral etoposide, including desired and undesired drug interactions (<italic toggle="yes">e.g.</italic> with ketoconazole), development of suitable drug delivery systems, use of more water-soluble prodrug of etoposide, and influence on gastric emptying. In addition to genotype-based dose administration, etoposide is suitable for pharmacokinetically guided dosing, which enables dose adjustments in individual patient.</p><p>Further, it is established that oral and intravenous schedules of etoposide in SCLC patients do not result in significant differences in treatment outcome, while results of toxicity are inconclusive. To conclude, the main message of the article is that better prediction of the pharmacokinetics of oral etoposide may encourage its wider use in routine clinical practice.</p></sec></abstract><kwd-group><kwd>oral etoposide</kwd><kwd>bioavailability</kwd><kwd>pharmacokinetic variability</kwd><kwd>small cell lung cancer</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec><title>Introduction</title><p>Etoposide is a topoisomerase II inhibiting anti-cancer drug, derived from podophyllotoxin. It has significant therapeutic activity in childhood leukemia, testicular tumors, Hodgkin&#8217;s disease, large cell lymphomas and small cell lung cancer (SCLC).<xref ref-type="bibr" rid="b1-rado-47-01-01">1</xref> In combined therapy with platinum compound (cisplatin or carboplatin), etoposide is used as a first-line therapy for SCLC, an aggressive disease with poor prognosis, which represents roughly 20% (15&#8211;25%) of all lung cancers.<xref ref-type="bibr" rid="b2-rado-47-01-01">2</xref>&#8211;<xref ref-type="bibr" rid="b7-rado-47-01-01">7</xref> With etoposide and cisplatin or carboplatin combination an overall response rate of approximately 75% can be anticipated. Radiation therapy to the thorax in addition to platinum/etoposide chemotherapy is associated with a small, but significant improvement in local control and overall survival in limited-stage disease.<xref ref-type="bibr" rid="b8-rado-47-01-01">8</xref> Progress in the management of SCLC has been modest in recent years as initial results of cisplatinum plus irinotecan showed improved survival. However these results were not confirmed in subsequent trials and cisplatinum/etoposide chemotherapy remains cornerstone of treatment for patients with SCLC.<xref ref-type="bibr" rid="b9-rado-47-01-01">9</xref>,<xref ref-type="bibr" rid="b10-rado-47-01-01">10</xref> In addition, some major contribution over the last 20 years has come also from radiotherapy.<xref ref-type="bibr" rid="b11-rado-47-01-01">11</xref></p><p>The mode of action of etoposide involves inhibition of topoisomerase II, a nuclear enzyme that is necessary for swivelling and relaxation of deoxyribonucleic acid (DNA) during replication and transcription. Etoposide inhibits the ability of topoisomerase II to relegate cleaved nucleic acid molecules by the formation and stabilisation of a topoisomerase II-etoposide-DNA ternary complex and thus increases topoisomerase II-mediated DNA breakage. The covalent topoisomerase II-cleaved DNA complex is normally a short-lived intermediate in the reaction and is tolerated by the cell. However, at high concentrations it has cytotoxic effects, probably due to impaired DNA repair, leading to apoptosis.<xref ref-type="bibr" rid="b12-rado-47-01-01">12</xref>,<xref ref-type="bibr" rid="b13-rado-47-01-01">13</xref></p><p>The activity of etoposide is dose- and schedule-dependent, and etoposide efficacy might be improved markedly with repeated drug administration.<xref ref-type="bibr" rid="b12-rado-47-01-01">12</xref>&#8211;<xref ref-type="bibr" rid="b17-rado-47-01-01">17</xref> Etoposide directly interacts with the ATP-bound enzyme monomer in such a way that each molecule of etoposide stabilizes only a single-stranded break. Depending on the dose of etoposide, single-stranded or double-stranded DNA breaks are generated.<xref ref-type="bibr" rid="b13-rado-47-01-01">13</xref>,<xref ref-type="bibr" rid="b14-rado-47-01-01">14</xref> Furthermore, the inhibition of topoisomerase II by etoposide is reversible and discontinuation of ternary complex allows quick DNA repair and diminishes the cytotoxicity of the drug. Thus, prolonged exposure to etoposide could increase the anticancer activity of the drug.<xref ref-type="bibr" rid="b12-rado-47-01-01">12</xref> Moreover, topoisomerase II is significantly expressed only in dividing cells during S and G2 phases of the cell cycle. Chronic scheduling maximizes the likelihood of exposing malignant cells to etoposide during sensitive periods of the cell cycle.<xref ref-type="bibr" rid="b14-rado-47-01-01">14</xref> However, myelosupression as the dose-limiting toxicity should be taken into account when planning the chemotherapy regimen.<xref ref-type="bibr" rid="b14-rado-47-01-01">14</xref> The chemotherapy treatment is therefore given in cycles, attacking cancer cells at their most sensitive periods, and allowing normal body cells time to recover.</p><p>A wide range of doses and schedules of etoposide are in use, depending on the treated disease. In patients with solid tumors, including SCLC, lower doses, such as 50&#8211;100 mg/m<sup>2</sup>/day over 3&#8211;5 days are suggested by some authors, while other authors suggest prolonged schedule as superior.<xref ref-type="bibr" rid="b18-rado-47-01-01">18</xref>&#8211;<xref ref-type="bibr" rid="b20-rado-47-01-01">20</xref> In most regimens etoposide is administered in cycles, which are usually repeated every 3&#8211;4 weeks.<xref ref-type="bibr" rid="b1-rado-47-01-01">1</xref>,<xref ref-type="bibr" rid="b21-rado-47-01-01">21</xref></p><p>Etoposide is commercially available in both intravenous and oral formulations. The oral formulation exhibits advantages for the patient as well as economic benefit compared with the intravenous one. The work from Liu and coworkers has indicated that 89% of incurable cancer patients preferred oral over intravenous chemotherapy, predominantly because of the convenience of administration, problems with intravenous access or needles, and a better chemotherapy-taking environment (outside of the clinic).<xref ref-type="bibr" rid="b22-rado-47-01-01">22</xref> In general, the quality of life of patients receiving palliative chemotherapy for advanced cancer was significantly poorer in patients treated at hospital compared with those treated at home.<xref ref-type="bibr" rid="b23-rado-47-01-01">23</xref> Most importantly, the oral formulation may provide an attractive alternative for patients who are unable to or have difficulty making the necessary and frequent visits to receive intravenous therapy.<xref ref-type="bibr" rid="b24-rado-47-01-01">24</xref> In comparison with intravenous infusion, oral administration of etoposide represents a significant cost saving for hospital and health insurance. Results of an economic analysis, which was conducted within a randomised multicentre study comparing the use of intravenous etoposide versus oral etoposide treatment in SCLC patients, reported a 17% savings for patients receiving the oral regimen. The following costs were examined: antineoplastic drugs, intravenous fluids, supplies used for chemotherapy administration, and chemotherapy administration procedure fees.<xref ref-type="bibr" rid="b25-rado-47-01-01">25</xref> Furthermore, the introduction of oral etoposide into combination chemotherapy regimens may shorten the hospitalization period and thus reduce non-drug related treatment costs as well.<xref ref-type="bibr" rid="b26-rado-47-01-01">26</xref></p><p>However, despite the numerous advantages of oral therapy, the intravenous formulation has been used more extensively.<xref ref-type="bibr" rid="b24-rado-47-01-01">24</xref> The main drawback of oral etoposide is its incomplete and variable bio-availability.<xref ref-type="bibr" rid="b27-rado-47-01-01">27</xref> Approximately 50% (30&#8211;97%) of the oral dose is bioavailable when compared with the intravenous route.<xref ref-type="bibr" rid="b26-rado-47-01-01">26</xref>&#8211;<xref ref-type="bibr" rid="b29-rado-47-01-01">29</xref> This means that the area under the curve (AUC) of a given oral dose is approximately 50% of what would be achieved after an intravenous dose. Additionally, variability in bioavailability was observed both within and between patients. Hande <italic toggle="yes">et al.</italic><xref ref-type="bibr" rid="b30-rado-47-01-01">30</xref> reported a mean etoposide bioavailability at a dose of 50 mg 64.6%, with intrapatient coefficient of variation (CV) 22.6% and interpatient CV 34.8%. A large CV suggests that some patients are receiving inadequate drug exposure, resulting in suboptimal tumor cytotoxicity, whereas others may be at risk for excess toxicity.<xref ref-type="bibr" rid="b30-rado-47-01-01">30</xref> This is particularly important when using drugs with a narrow therapeutic window, like etoposide.<xref ref-type="bibr" rid="b31-rado-47-01-01">31</xref> Additionally, a linear pharmacokinetic behaviour of oral etoposide was shown only for doses up to 200 mg.<xref ref-type="bibr" rid="b32-rado-47-01-01">32</xref> In higher doses, the percentage of absorbed etoposide may decrease while the CV in oral etoposide bioavailability may even increase.<xref ref-type="bibr" rid="b29-rado-47-01-01">29</xref></p><p>The absorption of etoposide is likely to depend on a number of interacting factors, the identification of which may be difficult. The improvement in the absorption of etoposide and the reduction in its variability, remain important goals to facilitate the clinical use of oral etoposide.<xref ref-type="bibr" rid="b27-rado-47-01-01">27</xref></p><p>This review focuses on the impact of various factors influencing bioavailability of etoposide, provides possibilities for its improvement and suggestions for treatment optimisation to ensure comparable pharmacokinetic parameters of oral and intravenous application. The review is restricted to treatment with etoposide in SCLC patients, for which etoposide-platinum doublet still represents the most effective standard therapy.</p></sec><sec><title>Bioavailability of oral etoposide</title><p>Bioavailability is the extent to which an administered drug enters the systemic circulation. It is defined by the AUC of the dose delivered by oral administration divided by the AUC of the intravenous application of the same dose. AUC of etoposide correlates with safety and efficacy as well as overall survival of patients with SCLC.<xref ref-type="bibr" rid="b33-rado-47-01-01">33</xref>,<xref ref-type="bibr" rid="b34-rado-47-01-01">34</xref> Oral administration may increase AUC variability because the drug must undergo additional processes such as being transported across the intestine, passing through the liver, and entering the systemic plasma circulation.<xref ref-type="bibr" rid="b30-rado-47-01-01">30</xref> Those are pharmacokinetic processes called absorption, first-pass metabolism and elimination prior entering the systemic circulation.<xref ref-type="bibr" rid="b35-rado-47-01-01">35</xref> Variation in the pharmacokinetics of a drug in a patient population is the net result of many complex interactions between genetic, physiological and environmental factors.<xref ref-type="bibr" rid="b36-rado-47-01-01">36</xref> The impact of these factors on pharmacokinetic processes and consequently AUC and bioavailability is described in some details in the following sections.</p><sec><title>Genetic factors</title><p>Genetic characteristics of metabolizing enzymes and transporters may influence drug blood level. Inherited differences in enzymes and transporters are known examples of pharmacogenetic variability. These factors may lead to inter-individual variation.<xref ref-type="bibr" rid="b37-rado-47-01-01">37</xref></p><p>Etoposide is a substrate of the efflux membrane transporters (ABC transporters) and metabolizing enzymes, which are located in the intestine and liver. Efflux membrane transporters limit the absorption of orally administered drug in the intestine and facilitate the pre-systemic elimination via bile, leading to poor bioavailability of drugs.<xref ref-type="bibr" rid="b38-rado-47-01-01">38</xref> A study aiming to characterize the regional absorptive and secretory kinetics of etoposide in rabbit intestinal tissues revealed that the apical to basolateral (<italic toggle="yes">i.e.</italic> absorptive) transport of etoposide was not apparently mediated by specialized transporters, whereas basolateral to apical (<italic toggle="yes">i.e.</italic> secretory) transport by intestinal tissues was concentration dependent and saturable, mediated by transporters.<xref ref-type="bibr" rid="b39-rado-47-01-01">39</xref></p><p>Etoposide was shown to be a substrate of several ABC transporters, notably ABCB1 (MDR1, P-glycoprotein, P-gp) and ABCC1 (MRP1), ABCC2 (MRP2), ABCC3 (MRP3) and ABCG2 (BCRP).<xref ref-type="bibr" rid="b40-rado-47-01-01">40</xref>&#8211;<xref ref-type="bibr" rid="b45-rado-47-01-01">45</xref> The location of these transporters in enterocytes and hepatocytes is marked in <xref ref-type="fig" rid="f1-rado-47-01-01">Figure 1</xref>. Allen <italic toggle="yes">et al.</italic><xref ref-type="bibr" rid="b40-rado-47-01-01">40</xref> showed that ABCB1 can have a substantial effect on the oral availability of etoposide, while ABCG2 can have a little effect on oral etoposide pharmacokinetics. <italic toggle="yes">In vitro</italic> data showed that ABCC2 and ABCC3 can moderately transport etoposide.<xref ref-type="bibr" rid="b42-rado-47-01-01">42</xref>,<xref ref-type="bibr" rid="b43-rado-47-01-01">43</xref> Etoposide was shown to be a good ABCC1 substrate.<xref ref-type="bibr" rid="b44-rado-47-01-01">44</xref> Lagas <italic toggle="yes">et al.</italic><xref ref-type="bibr" rid="b46-rado-47-01-01">46</xref> studied the impact of ABCB1, ABCC2 and ABCC3 on the pharmacokinetics of etoposide in wild-type, ABCC2<sup>&#8722;/&#8722;</sup>, ABCB1a/1b<sup>&#8722;/&#8722;</sup>, and ABCB1a/1b;ABCC2<sup>&#8722;/&#8722;</sup> mice. Results demonstrated that ABCB1, which is located in apical membrane of enterocytes, restricted the oral (re)uptake of unchanged etoposide, and mediated its excretion across the gut wall, while hepatobiliary excretion of both etoposide and etoposide glucuronide were almost entirely dependent on ABCC2, and not on ABCB1. Additionally, ABCC3 was responsible for the efflux of etoposide glucuronide from the liver to the systemic blood circulation, especially when ABCC2 was absent. Authors concluded that pharmacokinetics of etoposide and etoposide glucuronide is significantly affected by ABCB1, ABCC2, and ABCC3 and that high inter-individual variability of etoposide may be explained by variation in transporter expression or activity.<xref ref-type="bibr" rid="b46-rado-47-01-01">46</xref></p><p>Drug metabolism principally occurs in the liver, but also other tissues, like intestinal mucosa, must be considered.<xref ref-type="bibr" rid="b12-rado-47-01-01">12</xref> Etoposide is O-demethylated primarily by cytochrome P450 (CYP) 3A4 and to a lesser extent by CYP3A5.<xref ref-type="bibr" rid="b47-rado-47-01-01">47</xref>,<xref ref-type="bibr" rid="b48-rado-47-01-01">48</xref> Furthermore, CYP1A2 and 2E1 are involved as the minor enzymatic components in this metabolic pathway.<xref ref-type="bibr" rid="b49-rado-47-01-01">49</xref> O-demethylated metabolite of etoposide is catehol.<xref ref-type="bibr" rid="b47-rado-47-01-01">47</xref> Catehol can undergo oxidation to form an ortho-quinone (and vice versa) via formation of a semi-quinone free radical. Studies suggest that radical species, in addition to the catehol and ortho-quinone, might also be involved in the cytotoxicity of etoposide.<xref ref-type="bibr" rid="b50-rado-47-01-01">50</xref>&#8211;<xref ref-type="bibr" rid="b52-rado-47-01-01">52</xref> Ortho-quinone is attenuated by glutathione conjugation.<xref ref-type="bibr" rid="b53-rado-47-01-01">53</xref> The second way of etoposide metabolism is glucuronidation, mainly catalyzed by UGT1A1. Although etoposide glucuronidation is also catalyzed by UGT1A8 and 1A3, their activities are much lower than that of UGT1A1. The predominant form of etoposide glucuronide in liver and intestine is phenolic glucuronide, whereas two alcoholic glucuronides are the minor metabolites.<xref ref-type="bibr" rid="b54-rado-47-01-01">54</xref>,<xref ref-type="bibr" rid="b55-rado-47-01-01">55</xref> CYP isoform was reported to be directly involved in the oxidative metabolism of etoposide, therefore variation of the intestinal activity of this CYP isoform may directly affect the bioavailability of etoposide.<xref ref-type="bibr" rid="b12-rado-47-01-01">12</xref></p><p>As shown in <xref ref-type="fig" rid="f1-rado-47-01-01">Figure 1</xref>, once etoposide as a drug crosses the apical membrane of the enterocyte, a part is effluxed back to the intestinal lumen by ABC transporters ABCB1 (MDR1), ABCC2 (MRP2) and ABCG2 (BCRP) and part is possibly subjected to intestinal first-pass metabolism by metabolizing enzymes. The fraction of drug absorbed into the mesenteric blood circulation enters into the liver via the portal vein and may be transported from hepatocytes into the bile (metabolized or non-metabolized) or to the systemic circulation.<xref ref-type="bibr" rid="b56-rado-47-01-01">56</xref>,<xref ref-type="bibr" rid="b57-rado-47-01-01">57</xref></p><p>Many enzymes and secretory transporters are subject to genetic polymorphisms with functional consequences. A complete description of these polymorphisms can be found in the article of Robert <italic toggle="yes">et al</italic>.<xref ref-type="bibr" rid="b59-rado-47-01-01">59</xref> as well as on the dedicated websites (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="www.pharmgkb.org">www.pharmgkb.org</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="www.imm.ki.se/CYPalleles">www.imm.ki.se/CYPalleles</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="www.hapmap.org">www.hapmap.org</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="www.ncbi.nlm.nih.gov/projects/SNP/">www.ncbi.nlm.nih.gov/projects/SNP/</ext-link>). Genetic polymorphisms might be a one of the factors causing the interindividual differences in etoposide bioavailability. However, no study evaluated the association of these polymorphisms with etoposide bioavailability. Only one study explored the effect of polymorphisms in the <italic toggle="yes">ABCB1</italic> on etoposide pharmacokinetics. In this study <italic toggle="yes">ABCB1</italic> 3435TT genotype was associated with lower volume of distribution and contributed significantly to the inter-individual variability observed in etoposide pharmacokinetics.<xref ref-type="bibr" rid="b60-rado-47-01-01">60</xref> However, effects of <italic toggle="yes">ABCB1</italic> polymorphisms, particularly 3435C&gt;T, on digoxin plasma levels after oral administration were extensively studied.<xref ref-type="bibr" rid="b61-rado-47-01-01">61</xref>,<xref ref-type="bibr" rid="b62-rado-47-01-01">62</xref></p><p>Summarized, genetic variability and functional polymorphisms in ABC transporters are relevant pharmacological factors that have to be considered together with drug-metabolizing enzymes, whose activity show a large degree of interindividual variability.<xref ref-type="bibr" rid="b37-rado-47-01-01">37</xref></p></sec><sec><title>Physiological factors</title><p>The metabolism of etoposide is partly hepatic, therefore hepatic insufficiency causes an increase in bioavailability of etoposide due to decreased first-pass effect.<xref ref-type="bibr" rid="b12-rado-47-01-01">12</xref>,<xref ref-type="bibr" rid="b63-rado-47-01-01">63</xref> However, Hande <italic toggle="yes">et al.</italic><xref ref-type="bibr" rid="b29-rado-47-01-01">29</xref>,<xref ref-type="bibr" rid="b30-rado-47-01-01">30</xref> stated that variation in hepatic metabolism probably does not explain differences between oral and intravenous drug administration because etoposide&#8217;s hepatic clearance rate is not high. Aita <italic toggle="yes">et al.</italic><xref ref-type="bibr" rid="b64-rado-47-01-01">64</xref> studied the pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma and underlying cirrhosis. They found slightly high etoposide bioavailability and clearance resulting in a normal AUC.<xref ref-type="bibr" rid="b64-rado-47-01-01">64</xref> Bioavailability of etoposide was not affected neither in patients with gastric carcinoma nor in patients with gastrectomy.<xref ref-type="bibr" rid="b65-rado-47-01-01">65</xref></p><p>Ando <italic toggle="yes">et al.</italic><xref ref-type="bibr" rid="b66-rado-47-01-01">66</xref> showed that gender does not affect the pharmacokinetics or pharmacodynamics of oral etoposide, while patient&#8217;s age affect pharmacodynamics. Although there was no difference in pharmacokinetics between elderly (ages 75 years or older) and younger patients, equivalent exposure to etoposide resulted in greater pharmacodynamic sensitivity in elderly patients.<xref ref-type="bibr" rid="b66-rado-47-01-01">66</xref>,<xref ref-type="bibr" rid="b67-rado-47-01-01">67</xref> Contrary to the results of Ando <italic toggle="yes">et al.</italic><xref ref-type="bibr" rid="b66-rado-47-01-01">66</xref>, Miyazaki <italic toggle="yes">et al.</italic><xref ref-type="bibr" rid="b68-rado-47-01-01">68</xref> showed that, although there were no significant differences in mean AUC values, plasma clearance and urinary excretion of oral etoposide, there were significant differences in elimination half life and bioavailability in the elderly group, compared with the younger adult group; both were significantly increased in the elderly patients. In comparison with intravenous administration, there was no statistically significant difference in these parameters between the elderly and younger adult group.<xref ref-type="bibr" rid="b68-rado-47-01-01">68</xref></p></sec><sec><title>Environmental factors</title><p>Cancer patients commonly receive multiple medications, including chemotherapy and supportive care drugs, the majority of them are elderly, and so require medications for co-morbid conditions, and have age-related decline in hepatic and renal function that reduce their ability to metabolize and eliminate drugs.<xref ref-type="bibr" rid="b69-rado-47-01-01">69</xref> The possibility of drug-drug and drug-food interactions is therefore high. Interactions that affect bioavailability are usually pharmacokinetic interactions involving metabolising enzymes and drug transporters.</p><p>Many clinical and preclinical studies are documented wherein CYP450 and/or ABCB1 and/or UGT1A1 were prominently implicated to play an important role in etoposide bioavailability. Several CYP3A4 and ABCB1 inhibitors were described to enhance etoposide bioavailability, such as platinum compounds, cyclosporine A, hydroxyzine, quinidine, 20(S)-ginsenoside Rh2, GF120918, kaempferol, morin, quercetin, verapamil, PSC833 (valspodar), ketoconazole, piperine analogue and curcumin.</p><p>A study exploring the potential interaction between the two platinum drugs, cisplatin and carboplatin, and the oxidative metabolism of etoposide demonstrated that the interaction between etoposide and platinum drugs is small and the clinical impact is unlikely to be significant. The exact mechanism of interaction is unknown but may involve inhibition of etoposide metabolism.<xref ref-type="bibr" rid="b70-rado-47-01-01">70</xref></p><p>Cyclosporine A, hydroxyzine and quinidine were shown to increase systemic etoposide exposure through inhibition of the multidrug transporter ABCB1.<xref ref-type="bibr" rid="b71-rado-47-01-01">71</xref>&#8211;<xref ref-type="bibr" rid="b73-rado-47-01-01">73</xref> Increased AUC and additionally peak concentration (c<sub>max</sub>) was observed by co-administration of an ABCB1 inhibitor 20(S)-ginsenoside Rh2, a trace constituent of ginseng.<xref ref-type="bibr" rid="b74-rado-47-01-01">74</xref> Increased oral uptake of etoposide due to ABCB1 inhibition was shown also by GF120918.<xref ref-type="bibr" rid="b40-rado-47-01-01">40</xref></p><p>The oral bioavailability of etoposide increased significantly when the drug was combined with kaempferol, morin or quercetin, three ingredients of dietary supplements. Additionally, kaempferol also increased c<sub>max</sub> of oral etoposide. A possible explanation to enhanced bioavailability of oral etoposide by these three aforementioned drugs could be due to an inhibition of CYP450-catalyzed metabolism and ABCB1-mediated efflux in the intestine and/or liver.<xref ref-type="bibr" rid="b75-rado-47-01-01">75</xref>&#8211;<xref ref-type="bibr" rid="b77-rado-47-01-01">77</xref> Similar results were obtained with verapamil and PSC833 (valspodar), a CYP3A and ABCB1 inhibitor.<xref ref-type="bibr" rid="b40-rado-47-01-01">40</xref>,<xref ref-type="bibr" rid="b78-rado-47-01-01">78</xref>,<xref ref-type="bibr" rid="b79-rado-47-01-01">79</xref></p><p>Ketoconazole was also shown to increase systemic exposure of oral etoposide. Ketoconazole is a commonly used antifugal drug known for its inhibitory effect on CYP3A4, UGT1A1, and ABCB1. However, Peng Yong <italic toggle="yes">et al.</italic><xref ref-type="bibr" rid="b80-rado-47-01-01">80</xref> reported that increased systemic exposure to etoposide by ketoconazole modulation is most likely mediated through the inhibition of etoposide metabolism in the liver rather than the inhibition of the transporters in the intestine.<xref ref-type="bibr" rid="b80-rado-47-01-01">80</xref></p><p>The results of a study conducted by Harvey <italic toggle="yes">et al.</italic><xref ref-type="bibr" rid="b81-rado-47-01-01">81</xref> showed that food does not significantly interfere with etoposide bioavailability, at least at doses of 100 mg. Grapefruit juice increases the bioavailability of some orally-administered drugs that are metabolized by CYP3A4. However, Reif <italic toggle="yes">et al.</italic><xref ref-type="bibr" rid="b82-rado-47-01-01">82</xref> reported that coadministration of grapefruit juice causes an unexpected decrease in systemic exposure of oral etoposide. A possible explanation for the observed effect may be an alteration of the intestinal ABCB1-mediated transport.<xref ref-type="bibr" rid="b82-rado-47-01-01">82</xref> It was also shown that piperine analogue, a natural alkaloid of peppers significantly enhanced the plasma levels of etoposide. A mechanistic evaluation of this effect presented by Najar <italic toggle="yes">et al.</italic><xref ref-type="bibr" rid="b83-rado-47-01-01">83</xref> has shown that piperine analogue modifies ABCB1 and CYP3A4-mediated drug disposition mechanisms to enhance the intestinal absorption of etoposide, while preventing its efflux and metabolic inactivation during its transit from intestine to the systemic circulation. A similar effect was observed with curcumin which significantly increased the bioavailability of oral etoposide, while the pharmacokinetics of etoposide after intravenous application was not affected. Therefore, the enhanced oral bioavailability of etoposide in the presence of curcum might be due to inhibition of ABCB1 in the small intestine and possibly due to reduced first-pass metabolism via CYP3A also in the small intestine.<xref ref-type="bibr" rid="b84-rado-47-01-01">84</xref></p><p>Known interactions of oral etoposide with various drugs including their quantitative effects are summarized in <xref ref-type="table" rid="t1-rado-47-01-01">Table 1</xref>. To our knowledge, interactions with other drugs are not well documented; however, this does not necessarily mean no interactions exist.</p><p>Some other drugs, like ifosfamide<xref ref-type="bibr" rid="b34-rado-47-01-01">34</xref>, phenytoin and phenobarbitone<xref ref-type="bibr" rid="b85-rado-47-01-01">85</xref>, also modify systemic exposure (reduced AUC) of etoposide when administered concomitantly. However, in all these cases etoposide was administered intravenously.</p><p>On the other hand, low and variable etoposide bioavailability may be related also to its poor solubility in water and chemical instability in physiological fluids. Etoposide&#8217;s aqueous solubility is considered as extremely low. The mean solubility of etoposide at 37&#176;C over the pH range 1.30 to 10 is 116.44 to 167.25 &#956;g/ml, respectively.<xref ref-type="bibr" rid="b86-rado-47-01-01">86</xref> Assuming that stomach and intestine contain approximately 250 ml of fluid, the initial amount of solute in upper gastrointestinal tract is approximately 30 to 40 mg. Therefore, solubility may play an important role in higher doses.<xref ref-type="bibr" rid="b39-rado-47-01-01">39</xref> Extensive degradation of etoposide is observed at pH 1.30 and 10. The intrinsic dissolution rate of etoposide increase with temperature, however, its magnitude is far less than 1.0 mg/min/cm<sup>2</sup> at 37&#176;C, <italic toggle="yes">i.e.</italic> the absorption is limited by the dissolution rate. Additional proof for etoposide absorption to be dissolution rate limited rather than permeation rate limited is its partition coefficient between n-octanol and water which is 9.94 at 25&#176;C, reflecting etoposide&#8217;s high lipophilicity and consequently good permeability. The low aqueous solubility and slow intrinsic dissolution rate may account for the low and variable bioavailability of the drug. However, the problem of poor drug dissolution rate was resolved by the development of hydrophilic preparation: a soft gelatine capsule containing etoposide in the form of solution.<xref ref-type="bibr" rid="b87-rado-47-01-01">87</xref> Additional factors that could contribute to the low and erratic bioavailability of etoposide is its chemical instability in physiological (gastric and intestinal) solutions. It is known that pH of the gastrointestinal tract ranges from 1 to 8. Considering etoposide&#8217;s pH stability range, its maximal stability is at pH of 5&#8211;6.15, while it rapidly degrades at pH&lt;2.03 and pH&gt;8.<xref ref-type="bibr" rid="b30-rado-47-01-01">30</xref>,<xref ref-type="bibr" rid="b86-rado-47-01-01">86</xref><italic toggle="yes">In vitro</italic> studies showed that the decrease in stability in intestinal fluid at pH 7.5 is concentration-dependent while there is no concentration effect on stability in gastric fluid at pH 3.0.<xref ref-type="bibr" rid="b88-rado-47-01-01">88</xref></p></sec></sec><sec><title>Safety and efficacy of oral versus intravenous etoposide in SCLC</title><p>Safety and efficacy were shown to correlate with AUC of etoposide. Oral administration may increase the variability in AUC and may lead to a greater variability in safety and efficacy of oral etoposide.<xref ref-type="bibr" rid="b30-rado-47-01-01">30</xref></p><p>The first randomized phase II study compared 3-day oral <italic toggle="yes">vs</italic>. intravenous etoposide schedule in combination with cisplatin in SCLC patients, and assuming 50% bioavailability. Results of this study showed that overall response rates (complete and partial response), time to progression and survival were comparable for both treatment arms. Overall toxicity for both treatment arms was similar and included neutropenia, thrombocytopenia, anemia, alopecia, nausea, diarrhea, vomiting and weight loss. Septic episodes in neutropenic patients as well as moderate to severe anemia and more than 10% weight loss occurred more frequently with the intravenous when compared with the oral treatment. Based on this data it was concluded that the oral treatment regimen could be a suitable substitute for those patients to whom parenteral therapy cannot be given.<xref ref-type="bibr" rid="b24-rado-47-01-01">24</xref></p><p>Comparable results in terms of response were obtained in another SCLC study which compared safety and efficacy of intravenous and oral etoposide alone, in a 5-day schedule and not assuming 50% bioavailability. Intravenous dose was 80 mg/m<sup>2</sup>/day while oral dose was 130 mg/m<sup>2</sup>/day. Each study gave a similar response rate. The major dose-limiting factor, leukopenia, was observed more frequently in the intravenous administration. Other side effects were anemia, thrombocytopenia, anorexia, nausea, and alopecia<xref ref-type="bibr" rid="b89-rado-47-01-01">89</xref>,<xref ref-type="bibr" rid="b90-rado-47-01-01">90</xref></p><p>Yet, two other randomized studies compared oral and intravenous etoposide administration in combination with cisplatin for the treatment of SCLC patients. In both studies etoposide was administered intravenously for 3 days and oral etoposide was administered for 21 days. Self-evidently, the daily dose of intravenously administered etoposide was higher than the dose of orally administered one, while the cumulative dose of etoposide per cycle was higher for orally administered etoposide. Results of both studies showed that the two schedules of etoposide in combination with cisplatin did not result in significant differences in treatment outcome with respect to tumor response and survival. However, a significantly greater rate of hematologic toxicity was noted in intravenous etoposide treatment schedule in the first study<xref ref-type="bibr" rid="b91-rado-47-01-01">91</xref> and in oral etoposide treatment schedule in the second one.<xref ref-type="bibr" rid="b92-rado-47-01-01">92</xref></p><p>As expected, two randomized trials in patients with SCLC demonstrated that oral etoposide alone was inferior to intravenous combination treatment. Of note, although being less effective, oral etoposide alone was associated in the first trial with increased toxicity. However, in both studies intravenous etoposide was used in combined regimens with cisplatin or cyclophosphamide, doxorubicin, and vincristine, while oral etoposide was administered as monochemotherapy. Treatment schedules of oral and intravenous etoposide were also very different.<xref ref-type="bibr" rid="b93-rado-47-01-01">93</xref>,<xref ref-type="bibr" rid="b94-rado-47-01-01">94</xref></p><p>Aforementioned clinical trials are described in detail in <xref ref-type="table" rid="t2-rado-47-01-01">Table 2</xref>.</p></sec><sec><title>Improvement of bioavailability of oral etoposide</title><sec><title>Concomitant medications</title><p>Several strategies were explored to improve low and variable bioavailability of oral etoposide. A potential strategy for diminishing variability of oral etoposide is to minimize the sources of variability. Cancer patients are at especially high risk for drug interactions because they commonly receive multiple drugs. In addition, it is estimated that 50% of cancer patients use alternative and herbal medicines, often without their doctor&#8217;s knowledge. To diminish these risks, it is important to take an accurate medication history which should be updated at each visit. However, all predictable drug interactions are not always avoidable.<xref ref-type="bibr" rid="b69-rado-47-01-01">69</xref></p><p>Some drugs were reported to be intentionally used to modulate oral availability of etoposide when administered concomitantly. The increase in bioavailability is a consequence of inhibition of metabolic enzymes and/or efflux transporters. One of these drugs is ketoconazole.<xref ref-type="bibr" rid="b80-rado-47-01-01">80</xref> Combined use of etoposide with inhibitors of metabolizing enzymes and/or efflux transporters increases etoposide&#8217;s bioavailability. Allen <italic toggle="yes">et al</italic>.<xref ref-type="bibr" rid="b40-rado-47-01-01">40</xref> stated that raising the bioavailability closer to 100% might eliminate some variability and allow better control of etoposide exposure. On the contrary, Peng Yong <italic toggle="yes">et al</italic>.<xref ref-type="bibr" rid="b80-rado-47-01-01">80</xref> showed that ketoconazole does not reduce the variability.</p><p>However, modulation of intestinal absorption of drugs that are substrates of metabolic enzymes and transporters is further complicated by the recognition that polymorphic enzymes and transporters can modulate drug uptake.<xref ref-type="bibr" rid="b95-rado-47-01-01">95</xref></p></sec><sec sec-type="discussion"><title>Impact on drug and/or drug delivery system</title><p>To maximise bioavailability of oral etoposide, efforts should focus on ensuring rapid drug dissolution in the upper gastrointestinal tract, or delaying drug release to target the upper colon. These suggestions are based on results of directional study of etoposide from rabbit small intestine and colon which showed that secretory permeability was greatest in the ileum, whereas values in the upper small intestine and colon were approximately equal, and represented only 50% of the value in the ileum.<xref ref-type="bibr" rid="b39-rado-47-01-01">39</xref></p><p>Moreover, Zhang <italic toggle="yes">et al</italic>.<xref ref-type="bibr" rid="b96-rado-47-01-01">96</xref> have successfully incorporated etoposide into various modified nano-structured lipid carriers. Pharmacokinetic studies revealed improved relative bioavailability (more than 3.5-fold) of etoposide nanostructured lipid carriers to etoposide suspension in rats after oral administration. They elucidated that the enhanced bioavailability by the modified nanostructured lipid carrier formulation might be attributed to uptake of nanoparticles through the GI tract, increased permeability by surfactants, and decreased degradation and clearance.<xref ref-type="bibr" rid="b96-rado-47-01-01">96</xref> Furthermore, Wu <italic toggle="yes">et al</italic>.<xref ref-type="bibr" rid="b97-rado-47-01-01">97</xref> developed a phospholipid complex self-emulsifying drug delivery system. Compared with etoposide suspension, the relative bioavailability of this formulation after oral administration in rats was enhanced by 60.21-fold.<xref ref-type="bibr" rid="b97-rado-47-01-01">97</xref> Zhang <italic toggle="yes">et al</italic>.<xref ref-type="bibr" rid="b98-rado-47-01-01">98</xref> used natural solubilizer rubusoside to form etoposide-rubusoside nanoparticles. This method showed a better solubilization effect and capability of improving physical and chemical stability profiles than a softgel capsule containing etoposide in a vehicle consisting of citric acid, glycerin, purified water, and polyethylene glycol 400. This may improve bioavailability and clinical efficacy as well as improve safety, benefiting from the GRAS (generally regarded as safe) status of rubusoside.<xref ref-type="bibr" rid="b98-rado-47-01-01">98</xref> On another point, Mo <italic toggle="yes">et al</italic>.<xref ref-type="bibr" rid="b99-rado-47-01-01">99</xref> suggested N-octyl-O-sulfate chitosan to be used as a formulation excipient for etoposide, since it has a potential by inhibiting ABCB1 to improve the absorption of etoposide.</p><p>Etoposide phosphate, a more water-soluble prodrug of etoposide has also been suggested for oral administration in an attempt to increase bioavailability and reduce inter-individual variability. Chabot <italic toggle="yes">et al</italic>.<xref ref-type="bibr" rid="b100-rado-47-01-01">100</xref> reported a 19% higher extent of absorption for etoposide phosphate compared with literature data for oral etoposide while Sessa <italic toggle="yes">et al</italic>.<xref ref-type="bibr" rid="b101-rado-47-01-01">101</xref> reported comparable or only slightly better bioavailability of etoposide phosphate compared with oral etoposide. de Jong <italic toggle="yes">et al</italic>. <xref ref-type="bibr" rid="b102-rado-47-01-01">102</xref> found a small significant increase in bioavailability but inter-individual variability of bioavailability appeared to be unaltered.</p></sec><sec><title>Influence on the rate of gastric emptying</title><p>Joel <italic toggle="yes">et al</italic>.<xref ref-type="bibr" rid="b27-rado-47-01-01">27</xref> investigated the use of agents that may influence etoposide stability in gastrointestinal tract and, thereby, bioavailability. Results showed that drugs that influence the rate of gastric emptying (metoclopramide, propantheline), improve the stability of etoposide in artificial intestinal fluid (ethanol, bile salts), and that drugs that decrease stomach acidity (cimetidine) had no significant effect on improving the etoposide AUC.<xref ref-type="bibr" rid="b27-rado-47-01-01">27</xref></p></sec><sec><title>Individualization of etoposide dosage</title><p>Currently, the dose of etoposide is adjusted according to the body-surface area of the individual patient, but this does not yield the desired minimization in individual variation in the pharmacokinetics in adults.<xref ref-type="bibr" rid="b103-rado-47-01-01">103</xref></p><p>Etoposide is a suitable drug for pharmacokinetically guided dosing, because of its marked inter-individual pharmacokinetic variability, but relatively little intra-patient variation.<xref ref-type="bibr" rid="b104-rado-47-01-01">104</xref> Various studies have been performed with dose adjustments based on pharmacokinetic sampling. These studies have involved the administration of etoposide orally or intravenously to treat patients with different kinds of cancer.</p><p>Optimisation of oral etoposide dosage was investigated by El-Yazigi <italic toggle="yes">et al.</italic><xref ref-type="bibr" rid="b105-rado-47-01-01">105</xref> in elderly patients with non-Hodgkin&#8217;s lymphoma using individual fraction of dose absorbed and the therapeutic drug monitoring (TDM) approach. The extent of absorption (F) was calculated from the AUC generated from first oral and intravenous doses in the same patient. Etoposide was than given orally at a daily dose equivalent to D<sub>oral</sub>/F. The data obtained indicated that adjustment of the oral dose of etoposide in specific group of patients using individual bioavailability data and TDM approach yielded good safety and efficacy results while keeping the toxicity at the level that is similar to that of the intravenous administration.<xref ref-type="bibr" rid="b105-rado-47-01-01">105</xref></p><p>AUC is the best pharmacokinetic parameter for predicting anticancer pharmacodynamic effects. Precise estimation of AUC based on plasma concentration requires the handling of many blood samples, usually 8&#8211;12, which is expensive, time-consuming and inconvenient.<xref ref-type="bibr" rid="b12-rado-47-01-01">12</xref>,<xref ref-type="bibr" rid="b106-rado-47-01-01">106</xref> Several limited sampling models (LSM) that are based only on a few sparse determinations of plasma concentrations and can obtain a good estimate of the AUC for oral etoposide, were developed and validated.<xref ref-type="bibr" rid="b107-rado-47-01-01">107</xref>&#8211;<xref ref-type="bibr" rid="b109-rado-47-01-01">109</xref> Several such models were developed also for intravenous etoposide.<xref ref-type="bibr" rid="b106-rado-47-01-01">106</xref>,<xref ref-type="bibr" rid="b110-rado-47-01-01">110</xref>&#8211;<xref ref-type="bibr" rid="b112-rado-47-01-01">112</xref> The use of LSM in targeted dosing study was used in oral etoposide by Ando <italic toggle="yes">et al</italic>.<xref ref-type="bibr" rid="b113-rado-47-01-01">113</xref> and in intravenous etoposide by Lowis <italic toggle="yes">et al</italic>.<xref ref-type="bibr" rid="b114-rado-47-01-01">114</xref> Ando <italic toggle="yes">et al</italic>.<xref ref-type="bibr" rid="b113-rado-47-01-01">113</xref> reported that during the first 4 days of chemotherapy, one 25-mg capsule was taken three times daily. On day 5, the number of etoposide capsules was adjusted to the individualized dose, depending on the mean etoposide concentration on days 3 and 4, to achieve target concentration range of 1.0 to 1.5 &#956;g/ml.<xref ref-type="bibr" rid="b113-rado-47-01-01">113</xref></p><p>Another approach to optimizing etoposide dosing is to use population pharmacokinetics, which quantify pharmacokinetic variability among individuals who are the target population, and tries to explain the sources of variability. Individual pharmacokinetic parameters are estimated using the Bayesian approach by combining the population pharmacokinetic model with a limited number of plasma drug concentration measurments.<xref ref-type="bibr" rid="b12-rado-47-01-01">12</xref>,<xref ref-type="bibr" rid="b115-rado-47-01-01">115</xref></p><p>A population pharmacokinetics of oral etoposide was studied in patients with various tumor types by Nguyen <italic toggle="yes">et al</italic>.<xref ref-type="bibr" rid="b116-rado-47-01-01">116</xref> and Toffoli <italic toggle="yes">et al</italic>.<xref ref-type="bibr" rid="b117-rado-47-01-01">117</xref> They indicated that the renal function is the most important variable to be taken into account in etoposide dosing.<xref ref-type="bibr" rid="b116-rado-47-01-01">116</xref>,<xref ref-type="bibr" rid="b117-rado-47-01-01">117</xref></p><p>Ciccolini <italic toggle="yes">et al</italic>.<xref ref-type="bibr" rid="b118-rado-47-01-01">118</xref> presented a Bayesian method for performing dose adjustment of etoposide when administered intravenously. A Bayesian method was proven to efficiently adjust the experimental values to the target values, thus suggesting that this approach could be routinely used for therapeutic drug monitoring of etoposide.<xref ref-type="bibr" rid="b118-rado-47-01-01">118</xref></p><p>Functional polymorphisms in metabolizing enzymes and ABC transporters are another relevant factors that have to be considered in personalized medicine. The determination of functional polymorphisms in individual patient enables the use of genotype-based dose administration, to ensure minimal adverse drug reactions and maximal therapeutic efficacy.<xref ref-type="bibr" rid="b37-rado-47-01-01">37</xref>,<xref ref-type="bibr" rid="b119-rado-47-01-01">119</xref></p><p>On the other hand, pharmacodynamic model was developed and tested for TDM of 21-day oral etoposide in non-small cell lung cancer patients. The model was developed to predict the value of the neutrophil nadir as a function of the etoposide concentration. Depending of the target nadir (grade 3 neutropenia), the dose was adjusted. However, the pharmacodynamic model yields statistically significant results only when considering the population of patients. Conversely, when applied to individual patients for TDM, the model lacks accuracy and precision.<xref ref-type="bibr" rid="b120-rado-47-01-01">120</xref>,<xref ref-type="bibr" rid="b121-rado-47-01-01">121</xref></p></sec></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Generally, oral etoposide administration compared to intraveneous administration may result in an improvement of patient&#8217;s quality of life and reduced costs. Several studies confirmed comparable safety and efficacy of oral and intravenous etoposide. However, a greater use of oral etoposide is limited by its incomplete and variable bioavailability. Many researchers studied various factors that may influence etoposide bioavailability and, attempted to tailor etoposide dose to the individual patient. The strategy of limited sampling and estimation of individual pharmacokinetic parameters by the Bayesian method seems to efficiently adjust experimental values to the target value. Furthermore, dosage adjustment based on pharmacogenetic analysis may be of great importance for individualized treatment of cancer patients in future. Therefore, further studies are needed to show the accuracy and precision of Bayesian method and pharmacogenetic analysis in dosage adjustment of oral etoposide in SCLC patients.</p></sec></body><back><fn-group><fn id="fn1-rado-47-01-01"><p>Disclosure: No potential conflicts of interests were disclosed.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-rado-47-01-01"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Chabner</surname><given-names>BA</given-names></name><name name-style="western"><surname>Bertino</surname><given-names>J</given-names></name><name name-style="western"><surname>Cleary</surname><given-names>J</given-names></name><name name-style="western"><surname>Ortiz</surname><given-names>T</given-names></name><name name-style="western"><surname>Lane</surname><given-names>A</given-names></name><name name-style="western"><surname>Supko</surname><given-names>JG</given-names></name><etal/></person-group><article-title>Chapter 61. Cytotoxic agents</article-title><person-group person-group-type="editor"><name name-style="western"><surname>Brunton</surname><given-names>LL</given-names></name><name name-style="western"><surname>Chabner</surname><given-names>BA</given-names></name><name name-style="western"><surname>Knollmann</surname><given-names>BC</given-names></name></person-group><source>Goodman &amp; Gilman&#8217;s The pharmacological basis of therapeutics</source><edition>12th edition</edition><publisher-loc>New York</publisher-loc><publisher-name>McGraw-Hill</publisher-name><year>2011</year><comment>Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.accessmedicine.com/content.aspx?aID=16680251">http://www.accessmedicine.com/content.aspx?aID=16680251</ext-link>. Accessed April 16, 2012.</comment></element-citation></ref><ref id="b2-rado-47-01-01"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>S&#248;rensen</surname><given-names>M</given-names></name><name name-style="western"><surname>Pijls-Johannesma</surname><given-names>M</given-names></name><name name-style="western"><surname>Felip</surname><given-names>E</given-names></name></person-group><article-title>Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</article-title><source>Ann Oncol</source><year>2010</year><volume>21</volume><issue>Suppl 5</issue><fpage>v120</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">20555060</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdq172</pub-id></element-citation></ref><ref id="b3-rado-47-01-01"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuo</surname><given-names>YH</given-names></name><name name-style="western"><surname>Lin</surname><given-names>ZZ</given-names></name><name name-style="western"><surname>Yang</surname><given-names>YY</given-names></name><name name-style="western"><surname>Shao</surname><given-names>YY</given-names></name><name name-style="western"><surname>Shau</surname><given-names>WY</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>RN</given-names></name><etal/></person-group><article-title>Survival of patients with small cell lung carcinoma in Taiwan</article-title><source>Oncology</source><year>2012</year><volume>82</volume><fpage>19</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">22269348</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000335084</pub-id></element-citation></ref><ref id="b4-rado-47-01-01"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kagohashi</surname><given-names>K</given-names></name><name name-style="western"><surname>Ohara</surname><given-names>G</given-names></name><name name-style="western"><surname>Satoh</surname><given-names>H</given-names></name><name name-style="western"><surname>Sekizawa</surname><given-names>K</given-names></name></person-group><article-title>Chemotherapy for small-cell lung cancer with paraneoplastic nephritic syndrome</article-title><source>Radiol Oncol</source><year>2004</year><volume>38</volume><fpage>153</fpage><lpage>4</lpage></element-citation></ref><ref id="b5-rado-47-01-01"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dolen&#353;ek</surname><given-names>M</given-names></name><name name-style="western"><surname>Bav&#269;ar Vodovnik</surname><given-names>T</given-names></name></person-group><article-title>[Imaging detetection in early lung cancer]. [Slovenian]</article-title><source>Radiol Oncol</source><year>2006</year><volume>40</volume><issue>Suppl 1</issue><fpage>S53</fpage><lpage>8</lpage></element-citation></ref><ref id="b6-rado-47-01-01"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panov</surname><given-names>SZ</given-names></name></person-group><article-title>Molecular biology of the lung cancer</article-title><source>Radiol Oncol</source><year>2005</year><volume>39</volume><fpage>197</fpage><lpage>210</lpage></element-citation></ref><ref id="b7-rado-47-01-01"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ter&#269;elj</surname><given-names>M</given-names></name></person-group><article-title>[Early detetection of lung cancer]. [Slovenian]</article-title><source>Radiol Oncol</source><year>2006</year><volume>40</volume><issue>Suppl 1</issue><fpage>S59</fpage><lpage>66</lpage></element-citation></ref><ref id="b8-rado-47-01-01"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warde</surname><given-names>P</given-names></name><name name-style="western"><surname>Payne</surname><given-names>D</given-names></name></person-group><article-title>Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis</article-title><source>J Clin Oncol</source><year>1992</year><volume>10</volume><fpage>890</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">1316951</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.1992.10.6.890</pub-id></element-citation></ref><ref id="b9-rado-47-01-01"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noda</surname><given-names>K</given-names></name><name name-style="western"><surname>Nishiwaki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kawahara</surname><given-names>M</given-names></name><name name-style="western"><surname>Negoro</surname><given-names>S</given-names></name><name name-style="western"><surname>Sugiura</surname><given-names>T</given-names></name><name name-style="western"><surname>Yokoyama</surname><given-names>A</given-names></name><etal/></person-group><article-title>Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer</article-title><source>N Engl J Med</source><year>2002</year><volume>346</volume><fpage>85</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">11784874</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa003034</pub-id></element-citation></ref><ref id="b10-rado-47-01-01"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanna</surname><given-names>N</given-names></name><name name-style="western"><surname>Bunn</surname><given-names>PA</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Langer</surname><given-names>C</given-names></name><name name-style="western"><surname>Einhorn</surname><given-names>L</given-names></name><name name-style="western"><surname>Guthrie</surname><given-names>T</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Beck</surname><given-names>T</given-names></name><etal/></person-group><article-title>Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>2038</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">16648503</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2005.04.8595</pub-id></element-citation></ref><ref id="b11-rado-47-01-01"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Califano</surname><given-names>R</given-names></name><name name-style="western"><surname>Abidin</surname><given-names>AZ</given-names></name><name name-style="western"><surname>Peck</surname><given-names>R</given-names></name><name name-style="western"><surname>Faivre-Finn</surname><given-names>C</given-names></name><name name-style="western"><surname>Lorigan</surname><given-names>P</given-names></name></person-group><article-title>Management of small cell lung cancer. Recent Developments for Optimal Care</article-title><source>Drugs</source><year>2012</year><volume>72</volume><fpage>471</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">22356287</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/11597640-000000000-00000</pub-id></element-citation></ref><ref id="b12-rado-47-01-01"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toffoli</surname><given-names>G</given-names></name><name name-style="western"><surname>Corona</surname><given-names>G</given-names></name><name name-style="western"><surname>Basso</surname><given-names>B</given-names></name><name name-style="western"><surname>Boiocchi</surname><given-names>M</given-names></name></person-group><article-title>Pharmacokinetic optimisation of treatment with oral etoposide</article-title><source>Clin Pharmacokinet</source><year>2004</year><volume>43</volume><fpage>441</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15139794</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-200443070-00002</pub-id></element-citation></ref><ref id="b13-rado-47-01-01"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montecucco</surname><given-names>A</given-names></name><name name-style="western"><surname>Biamonti</surname><given-names>G</given-names></name></person-group><article-title>Cellular response to etoposide treatment</article-title><source>Cancer Lett</source><year>2007</year><volume>252</volume><fpage>9</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">17166655</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.canlet.2006.11.005</pub-id></element-citation></ref><ref id="b14-rado-47-01-01"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hande</surname><given-names>KR</given-names></name></person-group><article-title>The importance of drug scheduling in cancer chemotherapy: etoposide as an example</article-title><source>Oncologist</source><year>1996</year><volume>1</volume><fpage>234</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10387995</pub-id></element-citation></ref><ref id="b15-rado-47-01-01"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greco</surname><given-names>FA</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>DH</given-names></name><name name-style="western"><surname>Hande</surname><given-names>KR</given-names></name><name name-style="western"><surname>Porter</surname><given-names>LL</given-names></name><name name-style="western"><surname>Hainsworth</surname><given-names>JD</given-names></name><name name-style="western"><surname>Wolff</surname><given-names>SN</given-names></name></person-group><article-title>High-dose etoposide (VP-16) in small-cell lung cancer</article-title><source>Semin Oncol</source><year>1985</year><volume>12</volume><issue>Suppl 2</issue><fpage>42</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">2983434</pub-id></element-citation></ref><ref id="b16-rado-47-01-01"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slevin</surname><given-names>ML</given-names></name><name name-style="western"><surname>Clark</surname><given-names>PI</given-names></name><name name-style="western"><surname>Joel</surname><given-names>SP</given-names></name><name name-style="western"><surname>Malik</surname><given-names>S</given-names></name><name name-style="western"><surname>Osborne</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Gregory</surname><given-names>WM</given-names></name><etal/></person-group><article-title>A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer</article-title><source>J Clin Oncol</source><year>1989</year><volume>7</volume><fpage>1333</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">2549204</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.1989.7.9.1333</pub-id></element-citation></ref><ref id="b17-rado-47-01-01"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>AA</given-names></name><name name-style="western"><surname>Herndon</surname><given-names>JE</given-names><suffix>II</suffix></name><name name-style="western"><surname>Hollis</surname><given-names>DR</given-names></name><name name-style="western"><surname>Ellerton</surname><given-names>J</given-names></name><name name-style="western"><surname>Langleben</surname><given-names>A</given-names></name><name name-style="western"><surname>Richards</surname><given-names>F</given-names><suffix>II</suffix></name><etal/></person-group><article-title>Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive stage small-cell lung cancer: A randomized phase III study of the cancer and leukemia group B</article-title><source>Clin Oncol</source><year>1995</year><volume>13</volume><fpage>1871</fpage><lpage>9</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.1995.13.8.1871</pub-id><pub-id pub-id-type="pmid">7636529</pub-id></element-citation></ref><ref id="b18-rado-47-01-01"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seiter</surname><given-names>K</given-names></name></person-group><article-title>Toxicity of the topoisomerase II inhibitors</article-title><source>Expert Opin Drug Saf</source><year>2005</year><volume>4</volume><fpage>219</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">15794715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/14740338.4.2.219</pub-id></element-citation></ref><ref id="b19-rado-47-01-01"><label>19.</label><element-citation publication-type="journal"><comment>19</comment><person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>PI</given-names></name></person-group><article-title>Current role of oral etoposide in the management of small cell lung cancer</article-title><source>Drugs</source><year>1999</year><volume>58</volume><issue>Suppl 3</issue><fpage>17</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">10711837</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003495-199958003-00003</pub-id></element-citation></ref><ref id="b20-rado-47-01-01"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greco</surname><given-names>FA</given-names></name><name name-style="western"><surname>Hainsworth</surname><given-names>JD</given-names></name></person-group><article-title>Prolonged administration of low-daily dose etoposide: a superior dosing schedule?</article-title><source>Cancer Chemother Pharmacol</source><year>1994</year><volume>34</volume><fpage>101</fpage><lpage>4</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00684872</pub-id><pub-id pub-id-type="pmid">8070017</pub-id></element-citation></ref><ref id="b21-rado-47-01-01"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>S&#248;rensen</surname><given-names>M</given-names></name><name name-style="western"><surname>Felip</surname><given-names>E</given-names></name></person-group><article-title>Small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up</article-title><source>Ann Oncol</source><year>2009</year><volume>20</volume><issue>Suppl 4</issue><fpage>iv71</fpage><lpage>2</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdp133</pub-id><pub-id pub-id-type="pmid">19454469</pub-id></element-citation></ref><ref id="b22-rado-47-01-01"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>G</given-names></name><name name-style="western"><surname>Franssen</surname><given-names>E</given-names></name><name name-style="western"><surname>Fitch</surname><given-names>MI</given-names></name><name name-style="western"><surname>Warner</surname><given-names>E</given-names></name></person-group><article-title>Patient preferences for oral versus intravenous palliative chemotherapy</article-title><source>J Clin Oncol</source><year>1997</year><volume>15</volume><fpage>110</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">8996131</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.1997.15.1.110</pub-id></element-citation></ref><ref id="b23-rado-47-01-01"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Payne</surname><given-names>SA</given-names></name></person-group><article-title>A study of quality of life in cancer patients receiving palliative chemotherapy</article-title><source>Soc Sci Med</source><year>1992</year><volume>35</volume><fpage>1505</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">1283035</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0277-9536(92)90053-s</pub-id></element-citation></ref><ref id="b24-rado-47-01-01"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>DH</given-names></name><name name-style="western"><surname>Ruckdeschel</surname><given-names>JC</given-names></name><name name-style="western"><surname>Keller</surname><given-names>JH</given-names></name><name name-style="western"><surname>Lyman</surname><given-names>GH</given-names></name><name name-style="western"><surname>Kallas</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Macdonald</surname><given-names>J</given-names></name><etal/></person-group><article-title>A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer</article-title><source>Cancer</source><year>1991</year><volume>67</volume><fpage>245</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">1845847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1097-0142(19910101)67:1+&lt;245::aid-cncr2820671306&gt;3.0.co;2-z</pub-id></element-citation></ref><ref id="b25-rado-47-01-01"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pashko</surname><given-names>S</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>DH</given-names></name></person-group><article-title>Potential cost savings of oral versus intravenous etoposide in the treatment of small cell lung cancer</article-title><source>Pharmacoeconomics</source><year>1992</year><volume>1</volume><fpage>293</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">10147019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00019053-199201040-00006</pub-id></element-citation></ref><ref id="b26-rado-47-01-01"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujiwara</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ohune</surname><given-names>T</given-names></name><name name-style="western"><surname>Okusaki</surname><given-names>K</given-names></name><name name-style="western"><surname>Niitani</surname><given-names>K</given-names></name><name name-style="western"><surname>Sumiyoski</surname><given-names>H</given-names></name><name name-style="western"><surname>Takemoto</surname><given-names>V</given-names></name><etal/></person-group><article-title>Bioavailability of 50- and 75-mg oral etoposide in lung cancer patients</article-title><source>Cancer Chemother Pharmacol</source><year>1996</year><volume>37</volume><fpage>327</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">8548877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s002800050392</pub-id></element-citation></ref><ref id="b27-rado-47-01-01"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joel</surname><given-names>SP</given-names></name><name name-style="western"><surname>Clark</surname><given-names>PI</given-names></name><name name-style="western"><surname>Heap</surname><given-names>L</given-names></name><name name-style="western"><surname>Webster</surname><given-names>L</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>S</given-names></name><name name-style="western"><surname>Craft</surname><given-names>H</given-names></name><etal/></person-group><article-title>Pharmacological attempts to improve the bioavailability of oral etoposide</article-title><source>Cancer Chemother Pharmacol</source><year>1995</year><volume>37</volume><fpage>125</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">7497581</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00685639</pub-id></element-citation></ref><ref id="b28-rado-47-01-01"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harvey</surname><given-names>VJ</given-names></name><name name-style="western"><surname>Slevin</surname><given-names>ML</given-names></name><name name-style="western"><surname>Joel</surname><given-names>SP</given-names></name><name name-style="western"><surname>Barnett</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Smythe</surname><given-names>MM</given-names></name><name name-style="western"><surname>Ang</surname><given-names>LM</given-names></name><etal/></person-group><article-title>The pharmacokinetics of oral etoposide (VP16-213)</article-title><source>Proc Am Soc Clin Oncol</source><year>1984</year><volume>3</volume><fpage>24</fpage></element-citation></ref><ref id="b29-rado-47-01-01"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hande</surname><given-names>KR</given-names></name><name name-style="western"><surname>Krozely</surname><given-names>MG</given-names></name><name name-style="western"><surname>Greco</surname><given-names>FA</given-names></name><name name-style="western"><surname>Hainsworth</surname><given-names>JD</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>DH</given-names></name></person-group><article-title>Bioavailability of low-dose oral etoposide</article-title><source>J Clin Oncol</source><year>1993</year><volume>11</volume><fpage>374</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">8426216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.1993.11.2.374</pub-id></element-citation></ref><ref id="b30-rado-47-01-01"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hande</surname><given-names>K</given-names></name><name name-style="western"><surname>Messenger</surname><given-names>M</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>J</given-names></name><name name-style="western"><surname>Krozely</surname><given-names>M</given-names></name><name name-style="western"><surname>Kaul</surname><given-names>S</given-names></name></person-group><article-title>Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration</article-title><source>Clin Cancer Res</source><year>1999</year><volume>5</volume><fpage>2742</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">10537337</pub-id></element-citation></ref><ref id="b31-rado-47-01-01"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>W&#252;rthwein</surname><given-names>G</given-names></name><name name-style="western"><surname>Kr&#252;mpelmann</surname><given-names>S</given-names></name><name name-style="western"><surname>Tillmann</surname><given-names>B</given-names></name><name name-style="western"><surname>Real</surname><given-names>E</given-names></name><name name-style="western"><surname>Schulze-Westhoff</surname><given-names>P</given-names></name><name name-style="western"><surname>J&#252;rgens</surname><given-names>H</given-names></name><etal/></person-group><article-title>Population pharmacokinetic approach to compare oral and i.v. administration of etoposide</article-title><source>Anti-Cancer Drugs</source><year>1999</year><volume>10</volume><fpage>807</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">10587290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00001813-199910000-00003</pub-id></element-citation></ref><ref id="b32-rado-47-01-01"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slevin</surname><given-names>ML</given-names></name><name name-style="western"><surname>Joel</surname><given-names>SP</given-names></name><name name-style="western"><surname>Whomsley</surname><given-names>R</given-names></name><name name-style="western"><surname>Devenport</surname><given-names>K</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>VJ</given-names></name><name name-style="western"><surname>Osborne</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observation</article-title><source>Cancer Chemother Pharmacol</source><year>1989</year><volume>24</volume><fpage>329</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">2758563</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00304768</pub-id></element-citation></ref><ref id="b33-rado-47-01-01"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desoize</surname><given-names>B</given-names></name><name name-style="western"><surname>Mar&#233;chal</surname><given-names>F</given-names></name><name name-style="western"><surname>Cattan</surname><given-names>A</given-names></name></person-group><article-title>Correlations between clinical pharmacodynamics and pharmacokinetics of cisplatin and etoposide</article-title><source>Ann Biol Clin</source><year>1993</year><volume>51</volume><fpage>125</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">8214810</pub-id></element-citation></ref><ref id="b34-rado-47-01-01"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>You</surname><given-names>B</given-names></name><name name-style="western"><surname>Tranchand</surname><given-names>B</given-names></name><name name-style="western"><surname>Girard</surname><given-names>P</given-names></name><name name-style="western"><surname>Falandry</surname><given-names>C</given-names></name><name name-style="western"><surname>Ribba</surname><given-names>B</given-names></name><name name-style="western"><surname>Chabaud</surname><given-names>S</given-names></name><etal/></person-group><article-title>Etoposide pharmacokinetics and survival in patients with small cell lung cancer: A multicentre study</article-title><source>Lung Cancer</source><year>2008</year><volume>62</volume><fpage>261</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">18442869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lungcan.2008.03.008</pub-id></element-citation></ref><ref id="b35-rado-47-01-01"><label>35.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Roden</surname><given-names>DM</given-names></name></person-group><article-title>Chapter 5. Principles of Clinical Pharmacology</article-title><person-group person-group-type="editor"><name name-style="western"><surname>Longo</surname><given-names>DL</given-names></name><name name-style="western"><surname>Fauci</surname><given-names>AS</given-names></name><name name-style="western"><surname>Kasper</surname><given-names>DL</given-names></name><name name-style="western"><surname>Hauser</surname><given-names>SL</given-names></name><name name-style="western"><surname>Jameson</surname><given-names>JL</given-names></name><name name-style="western"><surname>Loscalzo</surname><given-names>J</given-names></name></person-group><source>Harrison&#8217;s principles of internal medicine</source><edition>18th edition</edition><publisher-loc>New York</publisher-loc><publisher-name>McGraw-Hill</publisher-name><year>2012</year><comment>Available form: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.accessmedicine.com/content.aspx?aID=9092427">http://www.accessmedicine.com/content.aspx?aID=9092427</ext-link>. Accessed April 16, 2012.</comment></element-citation></ref><ref id="b36-rado-47-01-01"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franke</surname><given-names>RM</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>ER</given-names></name><name name-style="western"><surname>Sparreboom</surname><given-names>A</given-names></name></person-group><article-title>Pharmacogenetics of drug transporters</article-title><source>Curr Pharm Des</source><year>2010</year><volume>16</volume><fpage>220</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">19835554</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/138161210790112683</pub-id></element-citation></ref><ref id="b37-rado-47-01-01"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brinkmann</surname><given-names>U</given-names></name><name name-style="western"><surname>Roots</surname><given-names>I</given-names></name><name name-style="western"><surname>Eichelbaum</surname><given-names>M</given-names></name></person-group><article-title>Pharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy</article-title><source>Drug Discov Today</source><year>2001</year><volume>6</volume><fpage>835</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11495756</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1359-6446(01)01892-x</pub-id></element-citation></ref><ref id="b38-rado-47-01-01"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dietrich</surname><given-names>CG</given-names></name><name name-style="western"><surname>Geier</surname><given-names>A</given-names></name><name name-style="western"><surname>Oude Elferink</surname><given-names>RPJ</given-names></name></person-group><article-title>ABC of oral bioavailability: transporters as gatekeepers in the gut</article-title><source>Gut</source><year>2003</year><volume>52</volume><fpage>1788</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">14633964</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gut.52.12.1788</pub-id><pub-id pub-id-type="pmcid">PMC1773875</pub-id></element-citation></ref><ref id="b39-rado-47-01-01"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kunta</surname><given-names>J</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J</given-names></name><name name-style="western"><surname>Makhey</surname><given-names>VD</given-names></name><name name-style="western"><surname>Sinko</surname><given-names>PJ</given-names></name></person-group><article-title>Active efflux kinetics of etoposide from rabbit small intestine and colon</article-title><source>Biopharm Drug Dispos</source><year>2000</year><volume>21</volume><fpage>83</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">11113881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1099-081x(200004)21:3&lt;83::aid-bdd220&gt;3.0.co;2-j</pub-id></element-citation></ref><ref id="b40-rado-47-01-01"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allen</surname><given-names>JD</given-names></name><name name-style="western"><surname>van Dort</surname><given-names>SC</given-names></name><name name-style="western"><surname>Buitelaar</surname><given-names>M</given-names></name><name name-style="western"><surname>van Tellingen</surname><given-names>O</given-names></name><name name-style="western"><surname>Schinkel</surname><given-names>AH</given-names></name></person-group><article-title>Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>1339</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">12649196</pub-id></element-citation></ref><ref id="b41-rado-47-01-01"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>A</given-names></name><name name-style="western"><surname>Marinaro</surname><given-names>W</given-names></name><name name-style="western"><surname>Hu</surname><given-names>P</given-names></name><name name-style="western"><surname>Sinko</surname><given-names>PJ</given-names></name></person-group><article-title>Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT)</article-title><source>Drug Metab Dispos</source><year>2002</year><volume>30</volume><fpage>457</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">11901101</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.30.4.457</pub-id></element-citation></ref><ref id="b42-rado-47-01-01"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>Y</given-names></name><name name-style="western"><surname>Konig</surname><given-names>J</given-names></name><name name-style="western"><surname>Buchholz</surname><given-names>JK</given-names></name><name name-style="western"><surname>Spring</surname><given-names>H</given-names></name><name name-style="western"><surname>Leier</surname><given-names>I</given-names></name><name name-style="western"><surname>Keppler</surname><given-names>D</given-names></name></person-group><article-title>Drug resistance and ATP-dependent conjugate transport mediated by the apikal multidrug resistance protein, MRP2, permanently expressed in human and canine cells</article-title><source>Mol Pharmacol</source><year>1999</year><volume>55</volume><fpage>929</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">10220572</pub-id></element-citation></ref><ref id="b43-rado-47-01-01"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kool</surname><given-names>M</given-names></name><name name-style="western"><surname>van der Linden</surname><given-names>M</given-names></name><name name-style="western"><surname>de Haas</surname><given-names>M</given-names></name><name name-style="western"><surname>Scheffer</surname><given-names>GL</given-names></name><name name-style="western"><surname>de Vree</surname><given-names>JM</given-names></name><name name-style="western"><surname>Smith</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>MRP3, an organic anion transporter able to transport anti-cancer drugs</article-title><source>Proc Nat Acad Sci USA</source><year>1999</year><volume>96</volume><fpage>6914</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10359813</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.96.12.6914</pub-id><pub-id pub-id-type="pmcid">PMC22016</pub-id></element-citation></ref><ref id="b44-rado-47-01-01"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wijnholds</surname><given-names>J</given-names></name><name name-style="western"><surname>Scheffer</surname><given-names>GL</given-names></name><name name-style="western"><surname>van der Valk</surname><given-names>M</given-names></name><name name-style="western"><surname>van der Valk</surname><given-names>P</given-names></name><name name-style="western"><surname>Beijnen</surname><given-names>JH</given-names></name><name name-style="western"><surname>Scheper</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage</article-title><source>J Exp Med</source><year>1998</year><volume>188</volume><fpage>797</fpage><lpage>808</lpage><pub-id pub-id-type="pmid">9730882</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.188.5.797</pub-id><pub-id pub-id-type="pmcid">PMC2213389</pub-id></element-citation></ref><ref id="b45-rado-47-01-01"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stephens</surname><given-names>RH</given-names></name><name name-style="western"><surname>O&#8217;Neill</surname><given-names>CA</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>J</given-names></name><name name-style="western"><surname>Humphrey</surname><given-names>M</given-names></name><name name-style="western"><surname>Henry</surname><given-names>B</given-names></name><name name-style="western"><surname>Rowland</surname><given-names>M</given-names></name></person-group><article-title>Resolution of P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a (&#8722;/&#8722;) mice</article-title><source>Br J Pharmacol</source><year>2002</year><volume>135</volume><fpage>2038</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">11959808</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.bjp.0704668</pub-id><pub-id pub-id-type="pmcid">PMC1573329</pub-id></element-citation></ref><ref id="b46-rado-47-01-01"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lagas</surname><given-names>JS</given-names></name><name name-style="western"><surname>Fan</surname><given-names>L</given-names></name><name name-style="western"><surname>Wagenaar</surname><given-names>E</given-names></name><name name-style="western"><surname>Vlaming</surname><given-names>MLH</given-names></name><name name-style="western"><surname>van Tellingen</surname><given-names>O</given-names></name><name name-style="western"><surname>Beijnen</surname><given-names>JH</given-names></name><etal/></person-group><article-title>P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide</article-title><source>Clin Cancer Res</source><year>2010</year><volume>16</volume><fpage>130</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">20028753</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-09-1321</pub-id></element-citation></ref><ref id="b47-rado-47-01-01"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Relling</surname><given-names>MV</given-names></name><name name-style="western"><surname>Nemec</surname><given-names>J</given-names></name><name name-style="western"><surname>Schuetz</surname><given-names>EG</given-names></name><name name-style="western"><surname>Schuetz</surname><given-names>JD</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Korzekwa</surname><given-names>KR</given-names></name></person-group><article-title>O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4</article-title><source>Mol Pharmacol</source><year>1994</year><volume>45</volume><fpage>352</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">8114683</pub-id></element-citation></ref><ref id="b48-rado-47-01-01"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhuo</surname><given-names>X</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>N</given-names></name><name name-style="western"><surname>Felix</surname><given-names>CA</given-names></name><name name-style="western"><surname>Blair</surname><given-names>IA</given-names></name></person-group><article-title>Kinetics and regulation of cytochrome P450-mediated etoposide metabolism</article-title><source>Drug Metab Dispos</source><year>2004</year><volume>32</volume><fpage>993</fpage><lpage>1000</lpage><pub-id pub-id-type="pmid">15319341</pub-id></element-citation></ref><ref id="b49-rado-47-01-01"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawashiro</surname><given-names>T</given-names></name><name name-style="western"><surname>Yamashita</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X-J</given-names></name><name name-style="western"><surname>Koyama</surname><given-names>E</given-names></name><name name-style="western"><surname>Tani</surname><given-names>M</given-names></name><name name-style="western"><surname>Chiba</surname><given-names>K</given-names></name><etal/></person-group><article-title>A study on the metabolism of etoposide and possible interactions with anti-tumor or supporting agents by human liver microsomes</article-title><source>J Pharmacol Exp Ther</source><year>1998</year><volume>286</volume><fpage>1294</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">9732391</pub-id></element-citation></ref><ref id="b50-rado-47-01-01"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mans</surname><given-names>DRA</given-names></name><name name-style="western"><surname>Ret&#232;l</surname><given-names>J</given-names></name><name name-style="western"><surname>van Maanen</surname><given-names>JMS</given-names></name><name name-style="western"><surname>Lafleur</surname><given-names>MVM</given-names></name><name name-style="western"><surname>van Schaik</surname><given-names>MA</given-names></name><name name-style="western"><surname>Pinedo</surname><given-names>HM</given-names></name><etal/></person-group><article-title>Role of the semi-quinone free radical of the anti-tumor agent etoposide (VP-16-213) in the inactivation of single- and double-stranded &#934;X174 DNA</article-title><source>Br J Cancer</source><year>1990</year><volume>62</volume><fpage>54</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">2167725</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/bjc.1990.228</pub-id><pub-id pub-id-type="pmcid">PMC1971739</pub-id></element-citation></ref><ref id="b51-rado-47-01-01"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Maanen</surname><given-names>JMS</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>J</given-names></name><name name-style="western"><surname>Pappie</surname><given-names>D</given-names></name><name name-style="western"><surname>van den Akker</surname><given-names>E</given-names></name><name name-style="western"><surname>Lafleur</surname><given-names>MVM</given-names></name><name name-style="western"><surname>Ret&#232;l</surname><given-names>J</given-names></name><etal/></person-group><article-title>Cytochrome P-450-mediated O-demethylation: A route in the metabolic activation of etoposide (VP-16-213)</article-title><source>Cancer Res</source><year>1987</year><volume>47</volume><fpage>4658</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">3621161</pub-id></element-citation></ref><ref id="b52-rado-47-01-01"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haim</surname><given-names>N</given-names></name><name name-style="western"><surname>Nemec</surname><given-names>J</given-names></name><name name-style="western"><surname>Roman</surname><given-names>J</given-names></name><name name-style="western"><surname>Sinha</surname><given-names>BK</given-names></name></person-group><article-title>In vitro metabolism of etoposide (VP-16-213) by liver microsomes and irreversible binding of reactive intermediates to microsomal proteins</article-title><source>Biochem Pharmacol</source><year>1987</year><volume>36</volume><fpage>527</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">3030329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0006-2952(87)90362-5</pub-id></element-citation></ref><ref id="b53-rado-47-01-01"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mans</surname><given-names>DR</given-names></name><name name-style="western"><surname>Lafleur</surname><given-names>MV</given-names></name><name name-style="western"><surname>Westmijze</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Horn</surname><given-names>IR</given-names></name><name name-style="western"><surname>Bets</surname><given-names>D</given-names></name><name name-style="western"><surname>Schuurhuis</surname><given-names>GJ</given-names></name><etal/></person-group><article-title>Reactions of glutathione with the catehol, the ortho-quinone and the semi-quinone free radical of etoposide. Consequences for DNA inactivation</article-title><source>Biochem Pharmacol</source><year>1992</year><volume>43</volume><fpage>1761</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">1315544</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0006-2952(92)90708-q</pub-id></element-citation></ref><ref id="b54-rado-47-01-01"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tallman</surname><given-names>MN</given-names></name><name name-style="western"><surname>Ali</surname><given-names>SY</given-names></name><name name-style="western"><surname>Smith</surname><given-names>PC</given-names></name></person-group><article-title>UDP-glucuronosyltransferase 1A1 Is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: Structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics</article-title><source>Drug Metab Dispos</source><year>2007</year><volume>35</volume><fpage>371</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">17151191</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.106.012732</pub-id></element-citation></ref><ref id="b55-rado-47-01-01"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watanabe</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nakajima</surname><given-names>M</given-names></name><name name-style="western"><surname>Ohashi</surname><given-names>N</given-names></name><name name-style="western"><surname>Kume</surname><given-names>T</given-names></name><name name-style="western"><surname>Yokoi</surname><given-names>T</given-names></name></person-group><article-title>Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1</article-title><source>Drug Metab Dispos</source><year>2003</year><volume>31</volume><fpage>589</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">12695347</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.31.5.589</pub-id></element-citation></ref><ref id="b56-rado-47-01-01"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Del Amo</surname><given-names>EM</given-names></name><name name-style="western"><surname>Heikkinen</surname><given-names>AT</given-names></name><name name-style="western"><surname>M&#246;nkk&#246;nen</surname><given-names>J</given-names></name></person-group><article-title>In vitro-in vivo correlation in p-glycoprotein mediated transport in intestinal absorption</article-title><source>Eur J Pharm Sci</source><year>2009</year><volume>36</volume><fpage>200</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">19063964</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejps.2008.11.005</pub-id></element-citation></ref><ref id="b57-rado-47-01-01"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matheny</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Lamb</surname><given-names>MW</given-names></name><name name-style="western"><surname>Brouwer</surname><given-names>KR</given-names></name><name name-style="western"><surname>Pollack</surname><given-names>GM</given-names></name></person-group><article-title>Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation</article-title><source>Pharmacotherapy</source><year>2001</year><volume>21</volume><fpage>778</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">11444575</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1592/phco.21.9.778.34558</pub-id></element-citation></ref><ref id="b58-rado-47-01-01"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kerb</surname><given-names>R</given-names></name></person-group><article-title>Implications of genetic polymorphisms in drug transporters for pharmacotherapy</article-title><source>Cancer Lett</source><year>2006</year><volume>234</volume><fpage>4</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">16504381</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.canlet.2005.06.051</pub-id></element-citation></ref><ref id="b59-rado-47-01-01"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robert</surname><given-names>J</given-names></name><name name-style="western"><surname>Le Morvan</surname><given-names>V</given-names></name><name name-style="western"><surname>Smith</surname><given-names>D</given-names></name><name name-style="western"><surname>Pourquier</surname><given-names>P</given-names></name><name name-style="western"><surname>Bonnet</surname><given-names>J</given-names></name></person-group><article-title>Predicting drug response and toxicity based on gene polymorphisms</article-title><source>Crit Rev Oncol Hematol</source><year>2005</year><volume>54</volume><fpage>171</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">15890268</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.critrevonc.2005.01.005</pub-id></element-citation></ref><ref id="b60-rado-47-01-01"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strother</surname><given-names>RM</given-names></name><name name-style="western"><surname>Jones</surname><given-names>D</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Younger</surname><given-names>A</given-names></name><name name-style="western"><surname>Einhorn</surname><given-names>LH</given-names></name><name name-style="western"><surname>Williams</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effect of the C3435T genetic polymorphism in MDR1 on etoposide pharmacokinetics</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><month>5</month><issue>20 suppl</issue><comment>abstr 2500</comment></element-citation></ref><ref id="b61-rado-47-01-01"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmeyer</surname><given-names>S</given-names></name><name name-style="western"><surname>Burk</surname><given-names>O</given-names></name><name name-style="western"><surname>von Richter</surname><given-names>O</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>H</given-names></name><name name-style="western"><surname>Brockmoller</surname><given-names>J</given-names></name><name name-style="western"><surname>Johne</surname><given-names>A</given-names></name><etal/></person-group><article-title>Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo</article-title><source>Proc Natl Acad Sci USA</source><year>2000</year><volume>97</volume><fpage>3473</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10716719</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.050585397</pub-id><pub-id pub-id-type="pmcid">PMC16264</pub-id></element-citation></ref><ref id="b62-rado-47-01-01"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakamura</surname><given-names>T</given-names></name><name name-style="western"><surname>Sakaeda</surname><given-names>T</given-names></name><name name-style="western"><surname>Horinouchi</surname><given-names>M</given-names></name><name name-style="western"><surname>Tamura</surname><given-names>T</given-names></name><name name-style="western"><surname>Aoyama</surname><given-names>N</given-names></name><name name-style="western"><surname>Shirakawa</surname><given-names>T</given-names></name><etal/></person-group><article-title>Effect of the mutation (C3435T) at exon 26 on the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects</article-title><source>Clin Pharmacol Ther</source><year>2002</year><volume>71</volume><fpage>297</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">11956513</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mcp.2002.122055</pub-id></element-citation></ref><ref id="b63-rado-47-01-01"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gerritsen-van Schieveen</surname><given-names>P</given-names></name><name name-style="western"><surname>Royer</surname><given-names>B</given-names></name></person-group><article-title>Level of evidence for therapeutic drug monitoring for etoposide after oral administration</article-title><source>Fundam Clin Pharmacol</source><year>2011</year><volume>25</volume><fpage>277</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">20608987</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1472-8206.2010.00856.x</pub-id></element-citation></ref><ref id="b64-rado-47-01-01"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aita</surname><given-names>P</given-names></name><name name-style="western"><surname>Robieux</surname><given-names>I</given-names></name><name name-style="western"><surname>Sorio</surname><given-names>R</given-names></name><name name-style="western"><surname>Tumolo</surname><given-names>S</given-names></name><name name-style="western"><surname>Corona</surname><given-names>G</given-names></name><name name-style="western"><surname>Cannizzaro</surname><given-names>R</given-names></name><etal/></person-group><article-title>Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma</article-title><source>Cancer Chemother Pharmacol</source><year>1999</year><volume>43</volume><fpage>287</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">10071979</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s002800050897</pub-id></element-citation></ref><ref id="b65-rado-47-01-01"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taal</surname><given-names>BG</given-names></name><name name-style="western"><surname>Beijnen</surname><given-names>JH</given-names></name><name name-style="western"><surname>Teller</surname><given-names>FG</given-names></name><name name-style="western"><surname>ten Bokkel Huinink</surname><given-names>WW</given-names></name><name name-style="western"><surname>Dubbelman</surname><given-names>R</given-names></name><name name-style="western"><surname>Boot</surname><given-names>H</given-names></name></person-group><article-title>Bioavailability of oral etoposide in gastric cancer</article-title><source>Eur J Cancer</source><year>1994</year><volume>30A</volume><fpage>420</fpage><lpage>1</lpage><pub-id pub-id-type="pmid">8204376</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0959-8049(94)90279-8</pub-id></element-citation></ref><ref id="b66-rado-47-01-01"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ando</surname><given-names>M</given-names></name><name name-style="western"><surname>Minami</surname><given-names>H</given-names></name><name name-style="western"><surname>Ando</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sakai</surname><given-names>S</given-names></name><name name-style="western"><surname>Shimono</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sugiura</surname><given-names>S</given-names></name><etal/></person-group><article-title>Pharmacological analysis of etoposide in elderly patients with lung cancer</article-title><source>Clin Cancer Res</source><year>1999</year><volume>5</volume><fpage>1690</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">10430070</pub-id></element-citation></ref><ref id="b67-rado-47-01-01"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fijiwara</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ohune</surname><given-names>T</given-names></name><name name-style="western"><surname>Niitani</surname><given-names>K</given-names></name><name name-style="western"><surname>Okusaki</surname><given-names>K</given-names></name><name name-style="western"><surname>Sumiyoshi</surname><given-names>H</given-names></name><name name-style="western"><surname>Ohashi</surname><given-names>N</given-names></name></person-group><article-title>Clinical pharmacological profile of etoposide in the elderly</article-title><source>Proc Am Soc Clin Oncol</source><year>1996</year><volume>15</volume><fpage>174</fpage></element-citation></ref><ref id="b68-rado-47-01-01"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miyazaki</surname><given-names>M</given-names></name><name name-style="western"><surname>Fujiwara</surname><given-names>Y</given-names></name><name name-style="western"><surname>Oguri</surname><given-names>T</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Ohune</surname><given-names>T</given-names></name><name name-style="western"><surname>Sumiyoshi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Clinical pharmacological profile of etoposide in elderly patients with lung cancer</article-title><source>Asia Pac J Clin Oncol</source><year>2005</year><volume>1</volume><fpage>92</fpage><lpage>7</lpage></element-citation></ref><ref id="b69-rado-47-01-01"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blower</surname><given-names>P</given-names></name><name name-style="western"><surname>de Wit</surname><given-names>R</given-names></name><name name-style="western"><surname>Goodin</surname><given-names>S</given-names></name><name name-style="western"><surname>Aapro</surname><given-names>M</given-names></name></person-group><article-title>Drug-drug interactions in oncology: Why are they important and can they be minimized?</article-title><source>Crit Rev Oncol Hematol</source><year>2005</year><volume>55</volume><fpage>117</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">15890526</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.critrevonc.2005.03.007</pub-id></element-citation></ref><ref id="b70-rado-47-01-01"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>HD</given-names></name><name name-style="western"><surname>Porter</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Bartelink</surname><given-names>I</given-names></name><name name-style="western"><surname>Nobbs</surname><given-names>JR</given-names></name><name name-style="western"><surname>Cole</surname><given-names>M</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>S</given-names></name><etal/></person-group><article-title>Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide</article-title><source>Br J Clin Pharmacol</source><year>2002</year><volume>53</volume><fpage>83</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">11849199</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.0306-5251.2001.01513.x</pub-id><pub-id pub-id-type="pmcid">PMC1874557</pub-id></element-citation></ref><ref id="b71-rado-47-01-01"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bisogno</surname><given-names>G</given-names></name><name name-style="western"><surname>Cowie</surname><given-names>F</given-names></name><name name-style="western"><surname>Boddy</surname><given-names>A</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>HD</given-names></name><name name-style="western"><surname>Dick</surname><given-names>G</given-names></name><name name-style="western"><surname>Pinkerton</surname><given-names>CR</given-names></name></person-group><article-title>High-dose cyclosporin with etoposide &#8211; toxicity and pharmacokinetic interaction in children with solid tumors</article-title><source>Br J Cancer</source><year>1998</year><volume>77</volume><fpage>2304</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9649150</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/bjc.1998.383</pub-id><pub-id pub-id-type="pmcid">PMC2150390</pub-id></element-citation></ref><ref id="b72-rado-47-01-01"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kan</surname><given-names>WM</given-names></name><name name-style="western"><surname>Liu</surname><given-names>YT</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>CL</given-names></name><name name-style="western"><surname>Shieh</surname><given-names>CY</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>JH</given-names></name><name name-style="western"><surname>Huang</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Effect of hydroxizide on the transport of etoposide in rat small intestine</article-title><source>Anticancer Drugs</source><year>2011</year><volume>12</volume><fpage>267</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">11290874</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00001813-200103000-00012</pub-id></element-citation></ref><ref id="b73-rado-47-01-01"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leu</surname><given-names>BL</given-names></name><name name-style="western"><surname>Huang</surname><given-names>JD</given-names></name></person-group><article-title>Inhibition of intestinal P-glycoprotein and effects on etoposide absorption</article-title><source>Cancer Chemother Pharmacol</source><year>1995</year><volume>35</volume><fpage>432</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">7850926</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s002800050258</pub-id></element-citation></ref><ref id="b74-rado-47-01-01"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>F</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ai</surname><given-names>H</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>20(S)-Ginsenoside Rh2 noncompetitively inhibits P-glycoprotein in vitro and in vivo: A case for herb-drug interactions</article-title><source>Drug Metab Dispos</source><year>2010</year><volume>38</volume><fpage>2179</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">20837659</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.110.034793</pub-id></element-citation></ref><ref id="b75-rado-47-01-01"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Choi</surname><given-names>JS</given-names></name></person-group><article-title>Enhanced bioavailability of etoposide after oral or intravenous administration of etoposide with kaempferol in rats</article-title><source>Arch Pharm Res</source><year>2009</year><volume>32</volume><fpage>133</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">19183886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12272-009-1127-z</pub-id></element-citation></ref><ref id="b76-rado-47-01-01"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Yun</surname><given-names>JK</given-names></name><name name-style="western"><surname>Choi</surname><given-names>JS</given-names></name></person-group><article-title>Effects of morin on the pharmacokinetics of etoposide in rats</article-title><source>Biopharm Drug Dispos</source><year>2007</year><volume>28</volume><fpage>151</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">17315145</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bdd.539</pub-id></element-citation></ref><ref id="b77-rado-47-01-01"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Choi</surname><given-names>JS</given-names></name></person-group><article-title>Effects of quercetin on the pharmacokinetics of Etoposide after oral or intravenous administration of etoposide in rats</article-title><source>Anticancer Res</source><year>2009</year><volume>29</volume><fpage>1411</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">19414395</pub-id></element-citation></ref><ref id="b78-rado-47-01-01"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piao</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Choi</surname><given-names>JS</given-names></name></person-group><article-title>Effects of verapamil on etoposide pharmacokinetics after intravenous and oral administration in rats</article-title><source>Eur J Drug Metab Pharmacokinet</source><year>2008</year><volume>33</volume><fpage>159</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">19007041</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF03191113</pub-id></element-citation></ref><ref id="b79-rado-47-01-01"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keller</surname><given-names>RP</given-names></name><name name-style="western"><surname>Altermatt</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Donatsch</surname><given-names>P</given-names></name><name name-style="western"><surname>Zihlmann</surname><given-names>H</given-names></name><name name-style="western"><surname>Laissue</surname><given-names>JA</given-names></name><name name-style="western"><surname>Hiestand</surname><given-names>PC</given-names></name></person-group><article-title>Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance <italic toggle="yes">in vivo</italic> cytostatic activity and toxicity</article-title><source>Int J Cancer</source><year>1992</year><volume>51</volume><fpage>433</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">1534319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.2910510316</pub-id></element-citation></ref><ref id="b80-rado-47-01-01"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng Yong</surname><given-names>W</given-names></name><name name-style="western"><surname>Desai</surname><given-names>AA</given-names></name><name name-style="western"><surname>Innocenti</surname><given-names>F</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>J</given-names></name><name name-style="western"><surname>Shepard</surname><given-names>D</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>K</given-names></name><etal/></person-group><article-title>Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer</article-title><source>Cancer Chemother Pharmacol</source><year>2007</year><volume>60</volume><fpage>811</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17308893</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-007-0428-5</pub-id></element-citation></ref><ref id="b81-rado-47-01-01"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harvey</surname><given-names>VJ</given-names></name><name name-style="western"><surname>Slevin</surname><given-names>ML</given-names></name><name name-style="western"><surname>Joel</surname><given-names>SP</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>A</given-names></name><name name-style="western"><surname>Wrigley</surname><given-names>PFM</given-names></name></person-group><article-title>The effect of food and concurent chemotherapy on the bioavailability of oral etoposide</article-title><source>Br J Cancer</source><year>1985</year><volume>52</volume><fpage>363</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">2994705</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/bjc.1985.202</pub-id><pub-id pub-id-type="pmcid">PMC1977207</pub-id></element-citation></ref><ref id="b82-rado-47-01-01"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reif</surname><given-names>S</given-names></name><name name-style="western"><surname>Nicolson</surname><given-names>MC</given-names></name><name name-style="western"><surname>Bisset</surname><given-names>D</given-names></name><name name-style="western"><surname>Reid</surname><given-names>M</given-names></name><name name-style="western"><surname>Kloft</surname><given-names>C</given-names></name><name name-style="western"><surname>Jaehde</surname><given-names>U</given-names></name><etal/></person-group><article-title>Effects of grapefruit juice intake on etoposide bioavailability</article-title><source>Eur J Clin Pharmacol</source><year>2002</year><volume>58</volume><fpage>491</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">12389073</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-002-0495-9</pub-id></element-citation></ref><ref id="b83-rado-47-01-01"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Najar</surname><given-names>IA</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>SC</given-names></name><name name-style="western"><surname>Singh</surname><given-names>GD</given-names></name><name name-style="western"><surname>Koul</surname><given-names>S</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>PN</given-names></name><name name-style="western"><surname>Javed</surname><given-names>S</given-names></name><etal/></person-group><article-title>Involvment of P-glycoprotein and CYP3A4 in the enhancement of etoposide bioavailability by a piperine analogue</article-title><source>Chem Biol Interact</source><year>2011</year><volume>190</volume><fpage>84</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">21333639</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cbi.2011.02.011</pub-id></element-citation></ref><ref id="b84-rado-47-01-01"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>CK</given-names></name><name name-style="western"><surname>Ki</surname><given-names>SH</given-names></name><name name-style="western"><surname>Choi</surname><given-names>JS</given-names></name></person-group><article-title>Effects of oral curcumin on the pharmacokinetics of intravenous and oral etoposide in rats: possible role of intestinal CYP3A and P-gp inhibition by curcumin</article-title><source>Biopharm Drug Dispos</source><year>2011</year><volume>32</volume><fpage>245</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">21506134</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bdd.754</pub-id></element-citation></ref><ref id="b85-rado-47-01-01"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodman</surname><given-names>JH</given-names></name><name name-style="western"><surname>Murry</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Madden</surname><given-names>T</given-names></name><name name-style="western"><surname>Santana</surname><given-names>VM</given-names></name></person-group><article-title>Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation</article-title><source>J Clin Oncol</source><year>1994</year><volume>12</volume><fpage>2390</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">7964955</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.1994.12.11.2390</pub-id></element-citation></ref><ref id="b86-rado-47-01-01"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>JC</given-names></name><name name-style="western"><surname>Chen</surname><given-names>JR</given-names></name><name name-style="western"><surname>Chow</surname><given-names>D</given-names></name></person-group><article-title>Preformulation study of etoposide: Identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide</article-title><source>Pharm Res</source><year>1989</year><volume>6</volume><fpage>408</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">2748532</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1023/a:1015935532725</pub-id></element-citation></ref><ref id="b87-rado-47-01-01"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slevin</surname><given-names>ML</given-names></name></person-group><article-title>The clinical pharmacology of etoposide</article-title><source>Cancer</source><year>1991</year><volume>67</volume><fpage>319</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">1984835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1097-0142(19910101)67:1+&lt;319::aid-cncr2820671319&gt;3.0.co;2-d</pub-id></element-citation></ref><ref id="b88-rado-47-01-01"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joel</surname><given-names>SP</given-names></name><name name-style="western"><surname>Clark</surname><given-names>PI</given-names></name><name name-style="western"><surname>Slevin</surname><given-names>ML</given-names></name></person-group><article-title>Stability of the i.v. and oral formulations of etoposide in solution</article-title><source>Cancer Chemother Pharmacol</source><year>1995</year><volume>37</volume><fpage>117</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">7497580</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00685638</pub-id></element-citation></ref><ref id="b89-rado-47-01-01"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arai</surname><given-names>R</given-names></name><name name-style="western"><surname>Kodema</surname><given-names>N</given-names></name><name name-style="western"><surname>Tsuruta</surname><given-names>M</given-names></name><name name-style="western"><surname>Furuse</surname><given-names>K</given-names></name><name name-style="western"><surname>Nishiwaki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nemoto</surname><given-names>E</given-names></name><etal/></person-group><article-title>A cooperative phase II study of NK 171 (etoposide) in small cell lung cancer &#8211; comparison of results between the intravenous administration and the oral administration</article-title><source>Lung Cancer</source><year>1986</year><volume>2</volume><fpage>110</fpage></element-citation></ref><ref id="b90-rado-47-01-01"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Furuse</surname><given-names>K</given-names></name></person-group><article-title>[A Phase II study of etoposide (NK171) in small cell lung cancer &#8211; comparison of results between intravenous administration and oral administration]. [Japanese]</article-title><source>Gan To Kagaku Ryoho</source><year>1985</year><volume>12</volume><fpage>2352</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">3000299</pub-id></element-citation></ref><ref id="b91-rado-47-01-01"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohno</surname><given-names>S</given-names></name><name name-style="western"><surname>Sugama</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sugiyama</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kitamura</surname><given-names>S</given-names></name></person-group><article-title>Comparison of chronic oral and intravenous etoposide administration in combination with cisplatin for the treatment of small cell lung cancer. [Abstract]</article-title><source>Lung Cancer</source><year>1991</year><volume>7</volume><issue>Suppl 1</issue><fpage>118</fpage></element-citation></ref><ref id="b92-rado-47-01-01"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>AA</given-names></name><name name-style="western"><surname>Herndon</surname><given-names>JE</given-names><suffix>2nd</suffix></name><name name-style="western"><surname>Hollis</surname><given-names>DR</given-names></name><name name-style="western"><surname>Ellerton</surname><given-names>J</given-names></name><name name-style="western"><surname>Langleben</surname><given-names>A</given-names></name><name name-style="western"><surname>Richards</surname><given-names>F</given-names><suffix>2nd</suffix></name><etal/></person-group><article-title>Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: A randomized phase III study of the cancer and leukemia group B</article-title><source>J Clin Oncol</source><year>1995</year><volume>13</volume><fpage>1871</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">7636529</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.1995.13.8.1871</pub-id></element-citation></ref><ref id="b93-rado-47-01-01"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Girling</surname><given-names>DJ</given-names></name></person-group><article-title>Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party</article-title><source>Lancet</source><year>1996</year><volume>348</volume><fpage>563</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">8774567</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0140-6736(96)02005-3</pub-id></element-citation></ref><ref id="b94-rado-47-01-01"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Souhami</surname><given-names>RL</given-names></name><name name-style="western"><surname>Spiro</surname><given-names>SG</given-names></name><name name-style="western"><surname>Rudd</surname><given-names>RM</given-names></name><name name-style="western"><surname>Ruiz de Elvira</surname><given-names>MC</given-names></name><name name-style="western"><surname>James</surname><given-names>LE</given-names></name><name name-style="western"><surname>Gower</surname><given-names>NH</given-names></name><etal/></person-group><article-title>Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy</article-title><source>J Natl Cancer Inst</source><year>1997</year><volume>89</volume><fpage>577</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">9106647</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/89.8.577</pub-id></element-citation></ref><ref id="b95-rado-47-01-01"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sparreboom</surname><given-names>A</given-names></name><name name-style="western"><surname>de Jonge</surname><given-names>MJA</given-names></name><name name-style="western"><surname>Verweij</surname><given-names>J</given-names></name></person-group><article-title>The use of oral cytotoxic and cytostatic drugs in cancer treatment</article-title><source>Eur J Cancer</source><year>2002</year><volume>38</volume><fpage>18</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">11750835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0959-8049(01)00322-7</pub-id></element-citation></ref><ref id="b96-rado-47-01-01"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Pan</surname><given-names>W</given-names></name></person-group><article-title>Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide</article-title><source>Eur J Pharm Sci</source><year>2011</year><volume>43</volume><fpage>174</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">21530654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejps.2011.04.005</pub-id></element-citation></ref><ref id="b97-rado-47-01-01"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Guo</surname><given-names>D</given-names></name><name name-style="western"><surname>Deng</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name></person-group><article-title>Preparation and evaluation of a self-emulsifying drug delivery sistem of etoposide-phospholipid complex</article-title><source>Drug Dev Ind Pharm</source><year>2011</year><volume>37</volume><fpage>103</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">21073324</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/03639045.2010.495752</pub-id></element-citation></ref><ref id="b98-rado-47-01-01"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><name name-style="western"><surname>Koh</surname><given-names>GY</given-names></name><name name-style="western"><surname>Hollingsworth</surname><given-names>J</given-names></name><name name-style="western"><surname>Russo</surname><given-names>PS</given-names></name><name name-style="western"><surname>Stout</surname><given-names>RW</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name></person-group><article-title>Reformulation of etoposide with solubility-enhancing rubusoside</article-title><source>Int J Pharm</source><year>2012</year><volume>434</volume><fpage>453</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">22698860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijpharm.2012.06.013</pub-id></element-citation></ref><ref id="b99-rado-47-01-01"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mo</surname><given-names>R</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Ping</surname><given-names>Q</given-names></name></person-group><article-title>Enhancing effect of N-octyl-O-sulfate chitosan on etoposide absorption</article-title><source>Int J Pharm</source><year>2011</year><volume>409</volume><fpage>38</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">21356302</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijpharm.2011.02.021</pub-id></element-citation></ref><ref id="b100-rado-47-01-01"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chabot</surname><given-names>GG</given-names></name><name name-style="western"><surname>Armand</surname><given-names>JP</given-names></name><name name-style="western"><surname>Terret</surname><given-names>C</given-names></name><name name-style="western"><surname>de Forni</surname><given-names>M</given-names></name><name name-style="western"><surname>Abigerges</surname><given-names>D</given-names></name><name name-style="western"><surname>Winograd</surname><given-names>B</given-names></name><etal/></person-group><article-title>Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study</article-title><source>J Clin Oncol</source><year>1996</year><volume>14</volume><fpage>2020</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">8683232</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.1996.14.7.2020</pub-id></element-citation></ref><ref id="b101-rado-47-01-01"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>96 Sessa</surname><given-names>C</given-names></name><name name-style="western"><surname>Zucchetti</surname><given-names>M</given-names></name><name name-style="western"><surname>Cerny</surname><given-names>T</given-names></name><name name-style="western"><surname>Pagani</surname><given-names>O</given-names></name><name name-style="western"><surname>Cavalli</surname><given-names>F</given-names></name><name name-style="western"><surname>De Fusco</surname><given-names>M</given-names></name><etal/></person-group><article-title>Phase I clinical and harmacokinetic study of oral etoposide phosphate</article-title><source>J Clin Oncol</source><year>1995</year><volume>13</volume><fpage>200</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">7799021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.1995.13.1.200</pub-id></element-citation></ref><ref id="b102-rado-47-01-01"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Jong</surname><given-names>RS</given-names></name><name name-style="western"><surname>Mulder</surname><given-names>NH</given-names></name><name name-style="western"><surname>Uges</surname><given-names>DRA</given-names></name><name name-style="western"><surname>Kaul</surname><given-names>S</given-names></name><name name-style="western"><surname>Winograd</surname><given-names>B</given-names></name><name name-style="western"><surname>Sleijfer</surname><given-names>DTh</given-names></name><etal/></person-group><article-title>Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide</article-title><source>Br J Cancer</source><year>1997</year><volume>75</volume><fpage>1660</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">9184183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/bjc.1997.282</pub-id><pub-id pub-id-type="pmcid">PMC2223531</pub-id></element-citation></ref><ref id="b103-rado-47-01-01"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathijssen</surname><given-names>RHN</given-names></name><name name-style="western"><surname>de Jong</surname><given-names>FA</given-names></name><name name-style="western"><surname>Loos</surname><given-names>WJ</given-names></name><name name-style="western"><surname>van der Bol</surname><given-names>JM</given-names></name><name name-style="western"><surname>Verweij</surname><given-names>J</given-names></name><name name-style="western"><surname>Sparreboom</surname><given-names>A</given-names></name></person-group><article-title>Flat-fixed dosing versus body surface area-based dosing of anticancer drugs in adults: does it make a difference?</article-title><source>Oncologist</source><year>2007</year><volume>12</volume><fpage>913</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">17766650</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1634/theoncologist.12-8-913</pub-id></element-citation></ref><ref id="b104-rado-47-01-01"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lowis</surname><given-names>SP</given-names></name><name name-style="western"><surname>Price</surname><given-names>L</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>ADJ</given-names></name><name name-style="western"><surname>Newell</surname><given-names>DR</given-names></name><name name-style="western"><surname>Cole</surname><given-names>M</given-names></name></person-group><article-title>A study of the feasibility and accuracy of pharmacokinetically guided etoposide dosing in children</article-title><source>Br J Cancer</source><year>1998</year><volume>77</volume><fpage>2318</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">9649152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/bjc.1998.385</pub-id><pub-id pub-id-type="pmcid">PMC2150379</pub-id></element-citation></ref><ref id="b105-rado-47-01-01"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Yazigi</surname><given-names>A</given-names></name><name name-style="western"><surname>Ezzat</surname><given-names>A</given-names></name><name name-style="western"><surname>Berry</surname><given-names>J</given-names></name><name name-style="western"><surname>Raines</surname><given-names>DA</given-names></name><name name-style="western"><surname>Yusuf</surname><given-names>A</given-names></name><name name-style="western"><surname>Al-Rawithi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Optimization of oral etoposide dosage in elderly patients with non-Hodgkin&#8217;s lymphoma using the fraction of dose absorbed measured for each patient</article-title><source>J Clin Pharmacol</source><year>2000</year><volume>40</volume><fpage>153</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">10664921</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/00912700022008801</pub-id></element-citation></ref><ref id="b106-rado-47-01-01"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holz</surname><given-names>JB</given-names></name><name name-style="western"><surname>K&#246;ppler</surname><given-names>H</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>L</given-names></name><name name-style="western"><surname>Fritsch</surname><given-names>HW</given-names></name><name name-style="western"><surname>Pfl&#252;ger</surname><given-names>KH</given-names></name><name name-style="western"><surname>Jungclas</surname><given-names>H</given-names></name></person-group><article-title>Limited sampling models for reliable estimation of etoposide area under the curve</article-title><source>Eur J Cancer</source><year>1995</year><volume>31A</volume><fpage>1794</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">8541103</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0959-8049(95)00383-t</pub-id></element-citation></ref><ref id="b107-rado-47-01-01"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gentili</surname><given-names>D</given-names></name><name name-style="western"><surname>Zucchetti</surname><given-names>M</given-names></name><name name-style="western"><surname>Torri</surname><given-names>V</given-names></name><name name-style="western"><surname>Sessa</surname><given-names>C</given-names></name><name name-style="western"><surname>de Jong</surname><given-names>J</given-names></name><name name-style="western"><surname>Cavalli</surname><given-names>F</given-names></name><etal/></person-group><article-title>A limited sampling model for the pharmacokinetics of etoposide given orally</article-title><source>Cancer Chemother Pharmacol</source><year>1993</year><volume>32</volume><fpage>482</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">8258198</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00685894</pub-id></element-citation></ref><ref id="b108-rado-47-01-01"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Millward</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Newell</surname><given-names>DR</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>K</given-names></name><name name-style="western"><surname>Matthews</surname><given-names>JP</given-names></name><name name-style="western"><surname>Balmanno</surname><given-names>K</given-names></name><name name-style="western"><surname>Charlton</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer</article-title><source>Cancer Chemother Pharmacol</source><year>1995</year><volume>37</volume><fpage>161</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">7497587</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00685644</pub-id></element-citation></ref><ref id="b109-rado-47-01-01"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Minami</surname><given-names>H</given-names></name><name name-style="western"><surname>Ando</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sakai</surname><given-names>S</given-names></name><name name-style="western"><surname>Shimokata</surname><given-names>K</given-names></name></person-group><article-title>Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide</article-title><source>J Clin Oncol</source><year>1995</year><volume>13</volume><fpage>191</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">7799020</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.1995.13.1.191</pub-id></element-citation></ref><ref id="b110-rado-47-01-01"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tranchand</surname><given-names>B</given-names></name><name name-style="western"><surname>Amsellem</surname><given-names>C</given-names></name><name name-style="western"><surname>Chatelut</surname><given-names>E</given-names></name><name name-style="western"><surname>Freyer</surname><given-names>G</given-names></name><name name-style="western"><surname>Iliadis</surname><given-names>A</given-names></name><name name-style="western"><surname>Ligneau</surname><given-names>B</given-names></name><etal/></person-group><article-title>A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients</article-title><source>Cancer Chemother Pharmacol</source><year>1999</year><volume>43</volume><fpage>316</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">10071983</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s002800050901</pub-id></element-citation></ref><ref id="b111-rado-47-01-01"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palle</surname><given-names>J</given-names></name><name name-style="western"><surname>Frost</surname><given-names>BM</given-names></name><name name-style="western"><surname>Gustafsson</surname><given-names>G</given-names></name><name name-style="western"><surname>Hellebostad</surname><given-names>M</given-names></name><name name-style="western"><surname>Kanerva</surname><given-names>J</given-names></name><name name-style="western"><surname>Liliemark</surname><given-names>E</given-names></name></person-group><article-title>Etoposide pharmacokinetics in children treated for acute myeloid leukaemia</article-title><source>Anticancer Drugs</source><year>2006</year><volume>17</volume><fpage>1087</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">17001183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.cad.0000231470.54288.49</pub-id></element-citation></ref><ref id="b112-rado-47-01-01"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lowis</surname><given-names>SP</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>ADJ</given-names></name><name name-style="western"><surname>Newell</surname><given-names>DR</given-names></name><name name-style="western"><surname>Cole</surname><given-names>M</given-names></name></person-group><article-title>Etoposide pharmacokinetics: the development and prospective validation of a dosing equation</article-title><source>Cancer Res</source><year>1993</year><volume>53</volume><fpage>4881</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">8402676</pub-id></element-citation></ref><ref id="b113-rado-47-01-01"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ando</surname><given-names>Y</given-names></name><name name-style="western"><surname>Minami</surname><given-names>H</given-names></name><name name-style="western"><surname>Saka</surname><given-names>H</given-names></name><name name-style="western"><surname>Ando</surname><given-names>M</given-names></name><name name-style="western"><surname>Sakai</surname><given-names>S</given-names></name><name name-style="western"><surname>Shimokata</surname><given-names>K</given-names></name></person-group><article-title>Therapeutic drug monitoring in 21-day oral etoposide treatment for lung cancer</article-title><source>Jpn J Cancer Res</source><year>1996</year><volume>87</volume><fpage>856</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">8797893</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1349-7006.1996.tb02111.x</pub-id><pub-id pub-id-type="pmcid">PMC5921180</pub-id></element-citation></ref><ref id="b114-rado-47-01-01"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lowis</surname><given-names>SP</given-names></name><name name-style="western"><surname>Price</surname><given-names>L</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>ADJ</given-names></name><name name-style="western"><surname>Newell</surname><given-names>DR</given-names></name><name name-style="western"><surname>Cole</surname><given-names>M</given-names></name></person-group><article-title>A study of the feasibility and accuracy of pharmacokinetically guided etoposide dosing in children</article-title><source>Br J Cancer</source><year>1998</year><volume>77</volume><fpage>2318</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">9649152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/bjc.1998.385</pub-id><pub-id pub-id-type="pmcid">PMC2150379</pub-id></element-citation></ref><ref id="b115-rado-47-01-01"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aarons</surname><given-names>L</given-names></name></person-group><article-title>Population pharmacokinetics: theory and practice</article-title><source>Br J Clin Pharmacol</source><year>1991</year><volume>31</volume><fpage>669</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">1768557</pub-id><pub-id pub-id-type="pmcid">PMC1368544</pub-id></element-citation></ref><ref id="b116-rado-47-01-01"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>I</given-names></name><name name-style="western"><surname>Chatelut</surname><given-names>E</given-names></name><name name-style="western"><surname>Chevreau</surname><given-names>C</given-names></name><name name-style="western"><surname>Tranchand</surname><given-names>B</given-names></name><name name-style="western"><surname>Lochon</surname><given-names>I</given-names></name><name name-style="western"><surname>Bachaud</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Population pharmacokinetics of total and unbound etoposide</article-title><source>Cancer Chemother Pharmacol</source><year>1998</year><volume>41</volume><fpage>125</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">9443625</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s002800050718</pub-id></element-citation></ref><ref id="b117-rado-47-01-01"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toffoli</surname><given-names>G</given-names></name><name name-style="western"><surname>Corona</surname><given-names>G</given-names></name><name name-style="western"><surname>Sorio</surname><given-names>R</given-names></name><name name-style="western"><surname>Robieux</surname><given-names>I</given-names></name><name name-style="western"><surname>Basso</surname><given-names>B</given-names></name><name name-style="western"><surname>Colussi</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Population pharmacokinetics and pharmacodynamics of oral etoposide</article-title><source>J Clin Pharmacol</source><year>2001</year><volume>52</volume><fpage>511</fpage><lpage>9</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.0306-5251.2001.01468.x</pub-id><pub-id pub-id-type="pmcid">PMC2014597</pub-id><pub-id pub-id-type="pmid">11736859</pub-id></element-citation></ref><ref id="b118-rado-47-01-01"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ciccolini</surname><given-names>J</given-names></name><name name-style="western"><surname>Monjanel-Mouterde</surname><given-names>S</given-names></name><name name-style="western"><surname>Bun</surname><given-names>SS</given-names></name><name name-style="western"><surname>Blanc</surname><given-names>C</given-names></name><name name-style="western"><surname>Duffaud</surname><given-names>F</given-names></name><name name-style="western"><surname>Favre</surname><given-names>R</given-names></name><etal/></person-group><article-title>Population pharmacokientics of etoposide: application to therapeutic drug monitoring</article-title><source>Ther Drug Monit</source><year>2002</year><volume>24</volume><fpage>709</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">12451286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007691-200212000-00005</pub-id></element-citation></ref><ref id="b119-rado-47-01-01"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nebert</surname><given-names>DW</given-names></name></person-group><article-title>Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist?</article-title><source>Am J Hum Genet</source><year>1997</year><volume>60</volume><fpage>265</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">9012398</pub-id><pub-id pub-id-type="pmcid">PMC1712416</pub-id></element-citation></ref><ref id="b120-rado-47-01-01"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>AA</given-names></name><name name-style="western"><surname>Tolley</surname><given-names>EA</given-names></name><name name-style="western"><surname>Niell</surname><given-names>HB</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>JP</given-names></name><name name-style="western"><surname>Mauer</surname><given-names>AM</given-names></name></person-group><article-title>Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer</article-title><source>J Clin Oncol</source><year>1993</year><volume>11</volume><fpage>1179</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">8388920</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.1993.11.6.1179</pub-id></element-citation></ref><ref id="b121-rado-47-01-01"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>AA</given-names></name><name name-style="western"><surname>Tolley</surname><given-names>EA</given-names></name><name name-style="western"><surname>Niell</surname><given-names>HB</given-names></name></person-group><article-title>Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small cell lung cancer</article-title><source>Clin Cancer Res</source><year>1998</year><volume>4</volume><fpage>1705</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">9676845</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-rado-47-01-01" position="float" orientation="portrait"><label>FIGURE 1.</label><caption><p>Schematic representation of the efflux transporters and metabolic enzymes (marked) possibly influencing etoposide bioavailability (modified by Ref. <xref ref-type="bibr" rid="b58-rado-47-01-01">58</xref>).</p><p>MDR1 = multi-drug resistance protein (ABCB1, P-glycoprotein); MRP1-3 = multidrug resistance-associated proteins (ABCC1-3); BCRP = breast-cancer resistance protein (ABCG2); CYPs = cytochrome P450</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="rado-47-01-01f1.jpg"/></fig><table-wrap id="t1-rado-47-01-01" position="float" orientation="portrait"><label>TABLE 1.</label><caption><p>Quantitative effects of etoposide interactions with various drugs that can potentially affect etoposide bioavailability</p></caption><table frame="hsides" rules="groups"><thead><tr content-type="background-color:#DEDEE5"><th align="left" valign="middle" rowspan="1" colspan="1"><bold>Drug</bold></th><th align="left" valign="middle" rowspan="1" colspan="1"><bold>Quantitative effect (method)</bold></th><th align="left" valign="middle" rowspan="1" colspan="1"><bold>Reference</bold></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Cisplatin or carboplatin</td><td align="left" valign="top" rowspan="1" colspan="1">Increased AUC of etoposide (8% with carboplatin, 28% with cisplatin) (patients, in vitro methods)</td><td align="left" valign="top" rowspan="1" colspan="1">Thomas <italic toggle="yes">et al.</italic><xref ref-type="bibr" rid="b70-rado-47-01-01">70</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cyclosporine A</td><td align="left" valign="top" rowspan="1" colspan="1">Mean increase of AUC of etoposide 89% (patients)</td><td align="left" valign="top" rowspan="1" colspan="1">Bisogno <italic toggle="yes">et al</italic>.<xref ref-type="bibr" rid="b71-rado-47-01-01">71</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hydroxyzine</td><td align="left" valign="top" rowspan="1" colspan="1">Transport of etoposide increased from the luminal site to the serosal site in the jejunum by 2-fold (reduced efflux) (everted rat gut sacks)</td><td align="left" valign="top" rowspan="1" colspan="1">Kan <italic toggle="yes">et al.</italic><xref ref-type="bibr" rid="b72-rado-47-01-01">72</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Quinidine</td><td align="left" valign="top" rowspan="1" colspan="1">Increased serum concentration of oral etoposide more than 2-fold (everted gut sacks prepared from rat jejunum and ileum)</td><td align="left" valign="top" rowspan="1" colspan="1">Leu <italic toggle="yes">et al.</italic><xref ref-type="bibr" rid="b73-rado-47-01-01">73</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">20(S)-Ginsenoside Rh2</td><td align="left" valign="top" rowspan="1" colspan="1">AUC of intragastric administration of etoposide in rats increased by 4.52-fold; c<sub>max</sub> increased by 2.54-fold (rats)</td><td align="left" valign="top" rowspan="1" colspan="1">Zhang <italic toggle="yes">et al.</italic><xref ref-type="bibr" rid="b74-rado-47-01-01">74</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GF120918</td><td align="left" valign="top" rowspan="1" colspan="1">Increased plasma levels of etoposide after oral administration 4&#8211;5-fold (wild-type mice)</td><td align="left" valign="top" rowspan="1" colspan="1">Allen <italic toggle="yes">et al.</italic><xref ref-type="bibr" rid="b40-rado-47-01-01">40</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Kaempferol</td><td align="left" valign="top" rowspan="1" colspan="1">The absolute bioavailability of oral etoposide increased by 11.0&#8211;12.3%; the relative bioavailability of oral etoposide increased 1.15&#8211;1.64-fold; significantly increased c<sub>max</sub> (rats)</td><td align="left" valign="top" rowspan="1" colspan="1">Li <italic toggle="yes">et al.</italic><xref ref-type="bibr" rid="b75-rado-47-01-01">75</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Morin</td><td align="left" valign="top" rowspan="1" colspan="1">Increased absolute bioavailability of oral etoposide by 35,9% (rats)</td><td align="left" valign="top" rowspan="1" colspan="1">Li <italic toggle="yes">et al</italic>.<xref ref-type="bibr" rid="b76-rado-47-01-01">76</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Quercetin</td><td align="left" valign="top" rowspan="1" colspan="1">Increased absolute bioavailability of oral etoposide to 12.7 (quercetin 5 mg/kg) or 13.6% (quercetin 15 mg/kg) (rats)</td><td align="left" valign="top" rowspan="1" colspan="1">Li <italic toggle="yes">et al.</italic><xref ref-type="bibr" rid="b77-rado-47-01-01">77</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Verapamil</td><td align="left" valign="top" rowspan="1" colspan="1">Increased absolute bioavailability of oral etoposide by 1.38 to 1.47-fold (rats)</td><td align="left" valign="top" rowspan="1" colspan="1">Piao <italic toggle="yes">et al.</italic><xref ref-type="bibr" rid="b78-rado-47-01-01">78</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PSC833 (valspodar)</td><td align="left" valign="top" rowspan="1" colspan="1">Increased plasma concentration of orally administered etoposide at least 10-fold (rats)</td><td align="left" valign="top" rowspan="1" colspan="1">Keller <italic toggle="yes">et al.</italic><xref ref-type="bibr" rid="b79-rado-47-01-01">79</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ketoconazole</td><td align="left" valign="top" rowspan="1" colspan="1">Increased AUC of oral etoposide by a median of 20% (patients)</td><td align="left" valign="top" rowspan="1" colspan="1">Peng Yong <italic toggle="yes">et al.</italic><xref ref-type="bibr" rid="b80-rado-47-01-01">80</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Food (standard breakfast: milk, cornflakes, sugar, egg, sausage, bread, margarine, orange marmalade and coffee or tea, sweetened to taste)</td><td align="left" valign="top" rowspan="1" colspan="1">Decreased AUC of oral etoposide from 40.8&#177;10.7 &#956;gml<sup>&#8722;1</sup>h1.7m<sup>&#8722;2</sup> to 35.8&#177;9.8 &#956;gml<sup>&#8722;1</sup>h1.7m<sup>&#8722;2</sup> (patients)</td><td align="left" valign="top" rowspan="1" colspan="1">Harvey <italic toggle="yes">et al.</italic><xref ref-type="bibr" rid="b81-rado-47-01-01">81</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Grapefruit juice</td><td align="left" valign="top" rowspan="1" colspan="1">Decreased AUC of oral etoposide of 26.2%; median absolute bioavailability of 50 mg oral etoposide with and without pretreatment with grapefruit juice was 52.4% and 73.2%, respectively (patients)</td><td align="left" valign="top" rowspan="1" colspan="1">Reif <italic toggle="yes">et al.</italic><xref ref-type="bibr" rid="b82-rado-47-01-01">82</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Piperine analogue</td><td align="left" valign="top" rowspan="1" colspan="1">Increased absolute bioavailability of oral etoposide 2.32-fold (in vitro and animal-derived models)</td><td align="left" valign="top" rowspan="1" colspan="1">Najar <italic toggle="yes">et al.</italic><xref ref-type="bibr" rid="b83-rado-47-01-01">83</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Curcumin</td><td align="left" valign="top" rowspan="1" colspan="1">Increased AUC of oral etoposide by 35.1% (curcumin 2 mg/kg) and 50.8% (curcumin 8 mg/kg); increased F of oral etoposide by 36.0% (curcumin 2 mg/kg) and 52.0% (curcumin 8 mg/kg) (rats)</td><td align="left" valign="top" rowspan="1" colspan="1">Lee <italic toggle="yes">et al.</italic><xref ref-type="bibr" rid="b84-rado-47-01-01">84</xref></td></tr></tbody></table></table-wrap><table-wrap id="t2-rado-47-01-01" position="float" orientation="portrait"><label>TABLE 2.</label><caption><p>Clinical trials evaluating safety and efficacy of oral <italic toggle="yes">vs</italic>. intravenous (i.v.) etoposide regimen in SCLC</p></caption><table frame="hsides" rules="groups"><thead><tr content-type="background-color:#DEDEE5"><th align="left" valign="middle" rowspan="2" colspan="1"><bold>Trial(ref.)</bold></th><th align="left" valign="middle" rowspan="2" colspan="1"><bold>Sample size</bold></th><th align="left" valign="middle" rowspan="2" colspan="1"><bold>Treatment regimen</bold></th><th colspan="4" align="center" valign="middle" rowspan="1"><bold>Results (oral etoposide regimen vs. i.v. etoposide regimen)</bold>
<hr/></th></tr><tr content-type="background-color:#DEDEE5"><th align="left" valign="middle" rowspan="1" colspan="1"><bold>ORR (%)</bold></th><th align="left" valign="middle" rowspan="1" colspan="1"><bold>mPFS (months)</bold></th><th align="left" valign="middle" rowspan="1" colspan="1"><bold>mOS (months)</bold></th><th align="left" valign="middle" rowspan="1" colspan="1"><bold>toxicity</bold></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="3" colspan="1">Randomized phase II<xref ref-type="bibr" rid="b24-rado-47-01-01">24</xref></td><td align="left" valign="top" rowspan="3" colspan="1">83 patients</td><td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">i.v. etoposide regimen (41 patients):</italic> cisplatin 100 mg/m<sup>2</sup> i.v. day 1, etoposide 120 mg/m<sup>2</sup> i.v. day 1&#8211;3</td><td align="left" valign="top" rowspan="3" colspan="1">50 vs. 59</td><td align="left" valign="top" rowspan="3" colspan="1">5.9 <italic toggle="yes">vs</italic>. 6.6</td><td align="left" valign="top" rowspan="3" colspan="1">8.6 for either treatment arm</td><td align="left" valign="top" rowspan="3" colspan="1">hematologic toxicity comparable in both treatment arms, infectious episodes, moderate to severe anemia and weight loss more predominant with the i.v regimen</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">oral etoposide regimen (42 patients):</italic> cisplatin 100 mg/m<sup>2</sup> i.v. day 1, etoposide 120 mg/m<sup>2</sup> i.v. day 1 and 240 mg/m<sup>2</sup> orally day 2 and 3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Every 4 weeks, maximum of 6 cycles.</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">Randomized phase II<xref ref-type="bibr" rid="b89-rado-47-01-01">89</xref>,<xref ref-type="bibr" rid="b90-rado-47-01-01">90</xref></td><td align="left" valign="top" rowspan="2" colspan="1">47 patients</td><td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">i.v. etoposide regimen (22 patients):</italic> etoposide 80 mg/m<sup>2</sup> i.v. 5 consecutive days</td><td align="left" valign="top" rowspan="2" colspan="1">similar for either treatment arm (PR: 28 vs. 36.4)</td><td align="left" valign="top" rowspan="2" colspan="1"><bold>/</bold></td><td align="left" valign="top" rowspan="2" colspan="1"><bold>/</bold></td><td align="left" valign="top" rowspan="2" colspan="1">leukopenia observed in 32% patients of the oral administration and in 59% patients of the i.v. administration</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">oral etoposide regimen (25 patients):</italic> etoposide 130 mg/m<sup>2</sup> orally 5 consecutive days</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">Randomized trial<xref ref-type="bibr" rid="b91-rado-47-01-01">91</xref></td><td align="left" valign="top" rowspan="3" colspan="1">21 patients</td><td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">i.v. etoposide regimen (14 patients):</italic> cisplatin 80 mg/m<sup>2</sup> i.v. day 1, etoposide 100 mg/m<sup>2</sup> i.v. day 2, 3 and 4</td><td align="left" valign="top" rowspan="3" colspan="1">86 <italic toggle="yes">vs</italic>. 64</td><td align="left" valign="top" rowspan="3" colspan="1"><bold>/</bold></td><td align="left" valign="top" rowspan="3" colspan="1">no significant difference</td><td align="left" valign="top" rowspan="3" colspan="1">hematologic toxicity less severe for oral regimen than for i.v. regimen</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">oral etoposide regimen (7 patients):</italic> cisplatin 80 mg/m<sup>2</sup> i.v. day 1, etoposide 50 mg orally day 3&#8211;23</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Both regimens were repeated every 4 weeks.</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">Randomized phase III<xref ref-type="bibr" rid="b92-rado-47-01-01">92</xref></td><td align="left" valign="top" rowspan="2" colspan="1">306</td><td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">i.v. etoposide regimen:</italic> cisplatin 25 mg/m<sup>2</sup> i.v. 3 days, etoposide 130 mg/m<sup>2</sup> i.v. 3 days<break/>Regimen was repeated every 21 days for 8 cycles.</td><td align="left" valign="top" rowspan="2" colspan="1">14 <italic toggle="yes">vs</italic>. 15 (PR: 47 <italic toggle="yes">vs</italic>. 42)</td><td align="left" valign="top" rowspan="2" colspan="1">7 months for either treatment arm</td><td align="left" valign="top" rowspan="2" colspan="1">9.9 <italic toggle="yes">vs</italic>. 9.5</td><td align="left" valign="top" rowspan="2" colspan="1">lethal toxicity due to neutropenia and infection: in 10% of patients on oral etoposide regimen and in 4% on i.v. etoposide regimen (difference not statistically significant)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">oral etoposide regimen:</italic> cisplatin 33 mg/m<sup>2</sup> i.v. 3 days, etoposide 50 mg/m<sup>2</sup> orally 21 days<break/>Regimen was repeated every 28 days for 6 cycles.</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">Randomized trial<xref ref-type="bibr" rid="b93-rado-47-01-01">93</xref></td><td align="left" valign="top" rowspan="2" colspan="1">339 patients</td><td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">i.v. etoposide regimen (168 patients):</italic> standard intravenous regimen of etoposide and vincristine, or cyclophosphamide, doxorubicin, and vincristine, 4 cycles</td><td align="left" valign="top" rowspan="2" colspan="1">45 <italic toggle="yes">vs</italic>. 51</td><td align="left" valign="top" rowspan="2" colspan="1"><bold>/</bold></td><td align="left" valign="top" rowspan="2" colspan="1">4.3 <italic toggle="yes">vs</italic>. 6.1</td><td align="left" valign="top" rowspan="2" colspan="1">grade 2 or worse haematological toxicity: in 29% of patients on oral etoposide regimen and in 21% on i.v. etoposide regimen</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">oral etoposide regimen (171 patients):</italic> etoposide 50 mg orally twice daily for 10 days, 4 cycles</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">Randomized trial<xref ref-type="bibr" rid="b94-rado-47-01-01">94</xref></td><td align="left" valign="top" rowspan="3" colspan="1">155 patients</td><td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">i.v. etoposide regimen (80 patients):</italic> intravenous regimen consisting of alternating cycles of etoposide and cisplatin and cyclophosphamide, doxorubicin, and vincristine</td><td align="left" valign="top" rowspan="3" colspan="1">32.9 <italic toggle="yes">vs</italic>. 46.3</td><td align="left" valign="top" rowspan="3" colspan="1">3.6 <italic toggle="yes">vs.</italic> 5.6</td><td align="left" valign="top" rowspan="3" colspan="1">4.8 <italic toggle="yes">vs</italic>. 5.9</td><td align="left" valign="top" rowspan="3" colspan="1">toxicity similar in the two treatment arms</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">oral etoposide regimen (75 patients):</italic> etoposide 100 mg orally twice daily for 5 days</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Both regimens were repeated every 21 days for 6 cycles.</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-rado-47-01-01"><p>ORR = overall response rate; mPFS = median progression free survival; mOS = median overall survival; PR = partial respons</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>